{"study_id": 102780, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review and assess controversial issues related to chronic HBV infection management, including the role of alanine aminotransferase (ALT) in defining treatment criteria.", "results_summary": "The abstract discusses debates on ALT upper limits, nomenclature for HBV infection phases, and antiviral therapy indications but does not provide specific findings on alanine's effects.", "population_specificity": "Patients with chronic HBV infection and HBV-cirrhosis.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:37.993681+00:00"}
{"study_id": 102782, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to validate and replicate dosimetry for ultra-high dose rate (UHDR) irradiation using alanine pellets among other dosimeters to establish a dosimetric consensus.", "results_summary": "Alanine provided the closest match between expected and measured dose in UHDR irradiation studies, with excellent agreement (\u00b13%) between replicate experiments, though with certain caveats related to absolute reference dose.", "population_specificity": "Not applicable (phantom study, no human or animal subjects).", "effective_dosage": "Expected doses of 7.5 to 16 Gy delivered at UHDR or conventional dose rates.", "study_duration": "Not specified (single irradiation sessions).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:38.960095+00:00"}
{"study_id": 102781, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the relationship between the Delta variant of COVID-19 and digestive system dysfunction, including the role of alanine aminotransferase (ALT) as a potential marker.", "results_summary": "The study found significant differences in abnormal ALT levels among COVID-19 severity groups, suggesting ALT as a transient marker for severe or critical Delta variant infection. Inactivated vaccines may help prevent severe symptoms and liver dysfunction.", "population_specificity": "Patients infected with the Delta variant of COVID-19, categorized into mild, moderate, and severe or critical illness groups.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:39.282018+00:00"}
{"study_id": 102784, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy of an amino acid-based ORS (VS002A) containing L-alanine against standard glucose-based WHO-ORS in reducing the duration of diarrhea in infants and young children.", "results_summary": "The study suggests that VS002A, which includes L-alanine, may enhance sodium and water absorption in the gut, potentially improving rehydration and bowel barrier function. However, the abstract does not provide specific outcome data, so the efficacy remains to be confirmed by trial results.", "population_specificity": "312 male children aged 6-36 months with acute non-bloody watery diarrhea.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:39.386460+00:00"}
{"study_id": 102783, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify factors associated with elevated serum AFP in HBV-infected patients with non-HCC and early-stage HCC and evaluate AFP's diagnostic performance for early-stage HCC detection.", "results_summary": "Antiviral therapy was negatively associated with elevated AFP, while HBeAg and AST > 1\u00d7 ULN were positively associated. AFP's diagnostic performance for early-stage HCC was better in patients with antiviral therapy, HBV DNA (\u2212), ALT \u2264 1\u00d7 ULN, and AST \u2264 1\u00d7 ULN.", "population_specificity": "4401 patients with chronic HBV infection (3680 non-HCC, 721 early-stage HCC).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:39.660707+00:00"}
{"study_id": 102785, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to identify patient characteristics, including baseline Alanine transaminase (ALT) levels, that modulate the effectiveness of intensive blood pressure and glycemic control on heart failure risk in type 2 diabetes patients.", "results_summary": "The study found that baseline ALT levels influenced the effectiveness of intensive blood pressure control for heart failure prevention, with only individuals in the lowest ALT tertile (8-19 mg/dl) benefiting significantly. No direct effects of Alanine itself were reported.", "population_specificity": "10,251 participants from the ACCORD glucose trial and 4,733 from the SBP sub-trial, all with type 2 diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:39.859956+00:00"}
{"study_id": 102779, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the longer-term efficacy and safety of pembrolizumab versus placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence, not specifically focused on Alanine.", "results_summary": "The study found that pembrolizumab improved disease-free survival compared to placebo, with increased alanine aminotransferase noted as a common adverse event in the pembrolizumab group. No deaths were attributed to pembrolizumab.", "population_specificity": "Adults aged 18+ with clear cell renal cell carcinoma at increased risk of recurrence post-nephrectomy.", "effective_dosage": "Pembrolizumab 200 mg intravenously every 3 weeks for up to 17 cycles.", "study_duration": "Up to 17 cycles (approximately 12.75 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:40.430475+00:00"}
{"study_id": 102786, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of periodontal treatment (scaling and root planning) in reducing alanine aminotransferase levels and Porphyromonas gingivalis IgG antibody titers in patients with NAFLD and periodontitis.", "results_summary": "The study found that scaling and root planning (SRP) significantly reduced alanine aminotransferase levels and P. gingivalis IgG antibody titers compared to tooth brushing, with no life-threatening events or treatment-related deaths reported.", "population_specificity": "Adult patients with NAFLD, periodontitis, alanine aminotransferase levels \u226540 U/L, and steatosis grade \u22651 (18 men and 22 women).", "effective_dosage": "Not specified (intervention was SRP or tooth brushing, not a dosage of alanine).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:40.979055+00:00"}
{"study_id": 102787, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were examining the effects of statins on cardiovascular disease prevention, not specifically focused on Alanine.", "results_summary": "The study did not focus on Alanine's effects but noted that statin therapy was not significantly associated with elevated alanine aminotransferase levels.", "population_specificity": "Adults at increased CVD risk without prior cardiovascular events.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Follow-up ranged from 6 months to 6 years.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:46.825211+00:00"}
{"study_id": 102791, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether probiotic supplementation influenced plasma alanine levels after Roux-Y gastric bypass (RYGB) surgery.", "results_summary": "The study found that alanine levels decreased in both the probiotic and placebo groups, but the reduction was significantly greater in the probiotic group (14.03%, p = 0.03). This suggests probiotics may enhance alanine metabolism post-RYGB.", "population_specificity": "31 patients who underwent RYGB surgery.", "effective_dosage": "Not specified (probiotic supplement: FloraVantage, containing Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:49.635006+00:00"}
{"study_id": 102788, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were comparing the safety and efficacy of nedaplatin-based versus cisplatin-based concurrent chemoradiotherapy in cervical cancer patients, not specifically evaluating alanine.", "results_summary": "The study found that nedaplatin had milder gastrointestinal reactions but more significant effects on liver function (including alanine aminotransferase levels) compared to cisplatin. No significant differences in overall survival or hematological toxicity were observed between the two groups.", "population_specificity": "Patients aged 28-82 years with pathologically diagnosed cervical cancer (stage IB-IVA).", "effective_dosage": "Weekly intravenous nedaplatin 30 mg/m\u00b2.", "study_duration": "Treatment administered between 10 May 2018 and 31 August 2020 (exact duration per patient not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:50.211047+00:00"}
{"study_id": 102792, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the progression of liver disease in children with cystic fibrosis (CF) who had nodular liver (NOD) detected via ultrasound versus those with normal liver (NL) findings.", "results_summary": "The study found that children with NOD developed clinically evident portal hypertension faster than those with NL, but there were no significant differences in growth or lung disease progression between the two groups. Platelet counts were lower in the NOD group at baseline compared to the NL group.", "population_specificity": "Children with cystic fibrosis (CF) and nodular liver (NOD) or normal liver (NL) findings.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:50.772879+00:00"}
{"study_id": 102794, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to develop a nomogram model using alanine aminotransferase (ALT) and other variables to predict the risk of nonalcoholic fatty liver disease (NAFLD) in Chinese individuals.", "results_summary": "The study found that ALT, along with age, sex, waist circumference, BMI, and triglycerides and glucose index, was a significant predictor of NAFLD. The nomogram model demonstrated high accuracy with AUROC values of 0.886 and 0.894 in the development and validation sets, respectively.", "population_specificity": "8,861 Chinese individuals aged 18-62 years undergoing physical examinations in Karamay.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:51.255536+00:00"}
{"study_id": 102793, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to analyze the effectiveness of lipid emulsion (LE) treatment for toxicity induced by nonlocal anesthetic drugs in pediatric patients, not specifically Alanine.", "results_summary": "The study found that LE improved symptoms of drug toxicity in 93.54% of pediatric patients, with 45.16% showing improvement within an hour. Adverse effects included elevated alanine aminotransaminases, but the focus was not on Alanine itself.", "population_specificity": "Pediatric patients (younger than 19 years) with toxicity from nonlocal anesthetic drugs.", "effective_dosage": "1.5 mL/kg LE bolus followed by 0.25 mL/kg/min continuous infusion.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:51.394157+00:00"}
{"study_id": 102790, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of mitapivat, an oral activator of pyruvate kinase, in reducing transfusion burden among adults with pyruvate kinase deficiency receiving regular transfusions.", "results_summary": "The study found that 37% of participants achieved a \u226533% reduction in transfusion burden. Common adverse events included increased alanine aminotransferase (37%), headache (37%), and fatigue (19%), with no treatment-related deaths reported.", "population_specificity": "Adults (\u226518 years) with pyruvate kinase deficiency receiving regular transfusions (at least six episodes in the previous year).", "effective_dosage": "5 mg, 20 mg, or 50 mg twice daily during a 16-week dose-optimization period, followed by a fixed dose for 24 weeks.", "study_duration": "40.3 weeks median exposure (16-week dose-optimization + 24-week fixed-dose period).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:51.414103+00:00"}
{"study_id": 102789, "supplement_id": 863, "safety_score": "68", "efficacy_score": 82, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of BFKB8488A (a bispecific antibody) in patients with type 2 diabetes mellitus (T2DM) or non-alcoholic fatty liver disease (NAFLD).", "results_summary": "BFKB8488A showed trends in exposure-dependent increases in HDL and decreases in triglycerides, as well as reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). In NAFLD patients, it led to significant liver fat reduction, with high-exposure tertiles showing a 49.0% decrease compared to placebo.", "population_specificity": "Patients with type 2 diabetes mellitus (T2DM) or non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Multiple doses at various levels and intervals (weekly, every 2 weeks, or every 4 weeks).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:53.274919+00:00"}
{"study_id": 102795, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of two isoenergetic diets (freshwater fish-based vs. alternating freshwater fish and red meat-based) on liver steatosis and gut microbiota in NAFLD patients, including the impact on alanine aminotransferase levels.", "results_summary": "The freshwater fish-based diet (F group) showed a significantly greater reduction in hepatic steatosis and improved alanine aminotransferase levels compared to the alternating diet (F/M group). Changes in gut microbiota and metabolites were also more pronounced in the F group.", "population_specificity": "34 patients with NAFLD and hepatic steatosis \u226510%.", "effective_dosage": "Not specified (isoenergetic intervention diets).", "study_duration": "84 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:57.570846+00:00"}
{"study_id": 102796, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the efficacy and safety of S-1 and irinotecan combination therapy in patients with EGFR-mutated non-small-cell lung cancer previously treated with EGFR tyrosine kinase inhibitors and platinum-based chemotherapy.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects.", "population_specificity": "Patients with EGFR-mutated non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitors and platinum-based chemotherapy.", "effective_dosage": "80 mg/m\u00b2 (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:58.562621+00:00"}
{"study_id": 102799, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the efficacy and safety of bosutinib, not Alanine, in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML).", "results_summary": "The study found that 60% of patients remained on bosutinib treatment at study completion, with cumulative rates of major molecular response (MMR) reported. Median treatment duration was 35.9 months.", "population_specificity": "Japanese patients with newly diagnosed CP-CML (n=60).", "effective_dosage": "400 mg once daily.", "study_duration": "Median duration of 35.9 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:01.160150+00:00"}
{"study_id": 102797, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the prevalence of Sj\u00f6gren's syndrome (SS) in primary biliary cholangitis (PBC) patients and assess its impact on PBC, including biochemical indicators like alanine transaminase (ALT).", "results_summary": "The study found no significant differences in ALT levels between PBC patients with and without SS, suggesting SS does not significantly alter ALT in PBC. Other biochemical and immunological markers showed varying impacts.", "population_specificity": "Adults with primary biliary cholangitis (PBC), some with concomitant Sj\u00f6gren's syndrome (SS).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:01.768141+00:00"}
{"study_id": 102801, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were testing the efficacy of rucaparib as a maintenance therapy following platinum-based chemotherapy in DRD biomarker-positive metastatic urothelial carcinoma patients.", "results_summary": "The study found that maintenance rucaparib extended progression-free survival (PFS) compared to placebo, with a median PFS of 35.3 weeks vs. 15.1 weeks, and was tolerable. Further investigation of PARP inhibition in selected mUC patients was deemed warranted.", "population_specificity": "DRD biomarker-positive metastatic urothelial carcinoma patients without cancer progression within 10 weeks of chemotherapy.", "effective_dosage": "600 mg twice daily orally.", "study_duration": "Until disease progression.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:01.930315+00:00"}
{"study_id": 102798, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of perioperative supplementation with a combination of L-glutamine, L-arginine, and \u03b2-hydroxy-\u03b2-methylbutyrate (HMB) on recovery, myocardial injury, and hospital stay duration in cardiac surgery patients.", "results_summary": "The study found that supplementation with Gln/Arg/HMB reduced serum levels of CPK-MB, troponin, bilirubin, and SOFA scores, as well as decreased hospital and ICU stay times compared to placebo. The results suggest improved recovery and reduced myocardial injury in cardiac surgery patients.", "population_specificity": "70 patients undergoing cardiac surgery (60 completed the study, mean age 53.13 \u00b1 14.35 years).", "effective_dosage": "2 sachets daily containing 7 g L-arginine, 7 g L-glutamine, and 1.5 g HMB.", "study_duration": "30 days before surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:03.896157+00:00"}
{"study_id": 102800, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to compare the effectiveness of obeticholic acid (OCA) and fibric acid derivatives (bezafibrate or fenofibrate) as second-line treatments for primary biliary cholangitis in patients inadequately responding to ursodeoxycholic acid.", "results_summary": "At 12 months, fibric acid derivatives showed a greater reduction in alkaline phosphatase (56.7%) compared to OCA (29.5%), but OCA led to higher normalization rates of serum alanine transaminase and bilirubin (55.9% and 36.4%, respectively). Biochemical response rates were similar between the two treatments (70.6% for OCA vs. 80% for fibric acids).", "population_specificity": "Patients with primary biliary cholangitis in the United Kingdom who inadequately responded to ursodeoxycholic acid.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:03.897601+00:00"}
{"study_id": 102802, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the efficacy and safety of Biejia-Ruangan tablet (CBRT) as an adjunctive therapy to entecavir for treating hepatic fibrosis in patients with chronic hepatitis B.", "results_summary": "The study found that CBRT combined with entecavir significantly improved serum biochemical markers (hyaluronic acid, laminin, pretype-III collagen, type IV collagen) and liver function indices (ALT, AST, TBiL) compared to entecavir alone, with a lower occurrence rate of adverse events.", "population_specificity": "Patients with chronic hepatitis B complicated by hepatic fibrosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:04.318019+00:00"}
{"study_id": 102804, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effect of continuous intake of salmon milt DNA on improving liver function, as measured by alanine aminotransferase (ALT) levels, in healthy participants.", "results_summary": "The study found that salmon milt DNA intake over 12 weeks improved liver function in participants with elevated ALT levels, though specific statistical outcomes are not detailed in the abstract.", "population_specificity": "50 healthy Japanese participants aged 30-70 years with ALT levels of 25-87 U/L.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:07.223114+00:00"}
{"study_id": 102806, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to synthesize data on the effects of Mediterranean Diet and Calorie Restriction interventions on NAFLD surrogate markers, including alanine aminotransferase (ALT), in adults.", "results_summary": "Dietary interventions, including calorie restriction and Mediterranean diet, significantly reduced ALT levels (P < 0.001 and P = 0.02, respectively), indicating improved liver function in NAFLD patients.", "population_specificity": "Adults with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:08.241348+00:00"}
{"study_id": 102807, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to identify predictors of mortality, including serum alanine aminotransferase levels, among severe COVID-19 patients in critical care units.", "results_summary": "Elevated alanine aminotransferase was identified as a predictor of mortality in severe COVID-19 patients, but the study did not assess its efficacy or safety as a supplement.", "population_specificity": "Confirmed SARS-CoV-2 patients admitted to critical care units in Nepal during the second wave of the pandemic.", "effective_dosage": "Not available", "study_duration": "Data collected over three months (April 14, 2021 to July 15, 2021).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:10.668397+00:00"}
{"study_id": 102808, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 30, "study_goal": "The researchers reported a case study of a patient with EBV-associated cholangiocarcinoma, noting elevated alanine aminotransferase levels as part of the diagnostic findings.", "results_summary": "The study described a patient with elevated alanine aminotransferase (242 U/L) as part of liver dysfunction but did not investigate alanine's effects or safety. The patient's condition deteriorated post-treatment, leading to death.", "population_specificity": "A 36-year-old female with EBV-associated poorly differentiated cholangiocarcinoma.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:11.399841+00:00"}
{"study_id": 102813, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of D-alanine as a potential augmentation strategy for treatment-resistant schizophrenia (TRS) by examining its impact on synaptic architecture and clinical outcomes.", "results_summary": "The study suggests that D-alanine, along with other D-amino acids, may serve as a promising augmentation therapy for TRS by modulating NMDAR function and improving cognitive deficits, though specific clinical outcomes for D-alanine alone were not detailed.", "population_specificity": "Patients with treatment-resistant schizophrenia (TRS), affecting 30-40% of schizophrenia cases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:13.891435+00:00"}
{"study_id": 102809, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and preliminary efficacy of cilofexor, a nonsteroidal farnesoid X receptor agonist, in treating primary sclerosing cholangitis (PSC) over a 96-week open-label extension phase.", "results_summary": "Cilofexor improved liver biochemistry and biomarkers of cholestasis and cellular injury, with significant reductions in GGT, ALT, AST, and serum C4, though ALP reductions were modest and not statistically significant. Safety was generally acceptable, with pruritus and other adverse events leading to discontinuation in 32% of subjects.", "population_specificity": "Noncirrhotic subjects with large-duct PSC (median age 44 years, 60% male, 60% with inflammatory bowel disease, 45% on ursodeoxycholic acid).", "effective_dosage": "100 mg daily", "study_duration": "96 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:14.539841+00:00"}
{"study_id": 102812, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare clinical characteristics and laboratory findings of COVID-19 patients with and without complications, including the role of alanine aminotransferase (ALT) as a prognostic biomarker.", "results_summary": "The study found elevated alanine aminotransferase (ALT) levels in COVID-19 patients, but it did not specifically assess the effects of alanine supplementation. ALT was among the biomarkers linked to disease severity.", "population_specificity": "75 confirmed COVID-19 positive patients, including 49 severely-ill cases.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:14.846008+00:00"}
{"study_id": 102810, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it examines the effect of mild moxibustion on cancer-related fatigue in NSCLC patients undergoing chemotherapy.", "results_summary": "The study found that mild moxibustion alleviated cancer-related fatigue in NSCLC patients but did not improve their quality of life. No adverse events or liver/kidney toxicity were reported.", "population_specificity": "Non-small-cell lung cancer (NSCLC) patients undergoing initial chemotherapy.", "effective_dosage": "Not applicable (study did not involve Alanine).", "study_duration": "Moxibustion was administered during chemotherapy for 30 minutes per day.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:16.332950+00:00"}
{"study_id": 102814, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The study aimed to investigate the effects of Clostridium butyricum capsules combined with rosuvastatin on intestinal flora, lipid metabolism, liver function, and inflammation in NAFLD patients, including the role of alanine aminotransferase (ALT) as a marker.", "results_summary": "The combination treatment significantly improved intestinal flora balance, reduced blood lipid levels, and alleviated liver fibrosis and function damage, including lower ALT levels, compared to rosuvastatin alone.", "population_specificity": "96 patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified for Clostridium butyricum capsules; rosuvastatin dosage not detailed.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:18.530204+00:00"}
{"study_id": 102815, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore associations between alanine aminotransferase (ALT) levels and other biochemical parameters in lean women with polycystic ovary syndrome (PCOS), identifying potential risk factors for liver impairment.", "results_summary": "Higher ALT levels were found in lean PCOS patients, positively correlated with BMI, total testosterone, white blood cell count, lymphocyte count, aspartate aminotransferase, and uric acid. Total testosterone and aspartate aminotransferase were independently associated with ALT after regression analysis, suggesting potential early liver impairment risk in lean PCOS women.", "population_specificity": "Lean women with PCOS (n=91) and healthy controls (n=45).", "effective_dosage": "Not specified", "study_duration": "Retrospective data reviewed from January 2019 to September 2021 (no explicit intervention duration).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:19.496604+00:00"}
{"study_id": 102816, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effectiveness of silymarin nanomicelles on symptom resolution, laboratory parameters, and liver enzymes (including alanine aminotransferase) in COVID-19 patients.", "results_summary": "The study found no significant differences between silymarin and placebo groups in symptom resolution time, laboratory parameters, or hospitalization duration. However, alanine aminotransferase levels decreased significantly in the treatment group compared to placebo.", "population_specificity": "Patients with COVID-19 (n=50, split into treatment and placebo groups).", "effective_dosage": "70 mg silymarin as nanomicelles, three times daily.", "study_duration": "Two weeks.", "interactions": "Concomitant use of dexamethasone and remdesivir might obscure silymarin's effects.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:21.853377+00:00"}
{"study_id": 102818, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to assess the clinical effects of wheat germ, including its impact on alanine aminotransferase (ALT) levels, in patients with NAFLD.", "results_summary": "The study found that wheat germ consumption significantly reduced serum alanine aminotransferase (ALT) levels, along with improvements in hepatic steatosis, total cholesterol, triglycerides, and antioxidant capacity in NAFLD patients compared to placebo.", "population_specificity": "Fifty participants with NAFLD, randomly allocated to wheat germ or placebo groups.", "effective_dosage": "40 g wheat germ daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:23.382479+00:00"}
{"study_id": 102817, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical and biological safety of pyronaridine-artesunate (PA), with a focus on hepatotoxicity markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), in real-life conditions for malaria treatment.", "results_summary": "The study found that PA was well-tolerated, with 97.8% of patients reporting no adverse events. No clinical or biological hepatotoxicity related to PA was observed, and biochemistry parameters remained within normal ranges.", "population_specificity": "Patients with uncomplicated malaria attending health facilities in Nanoro, Burkina Faso.", "effective_dosage": "PA administered orally once a day for 3 days.", "study_duration": "28-day follow-up after treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:23.449811+00:00"}
{"study_id": 102821, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the role of Mycobacterium w (Mw) along with standard care in critically ill COVID-19 patients, including its impact on laboratory parameters and clinical outcomes.", "results_summary": "Mw plus standard care was associated with higher mortality and longer hospital stays, but early initiation (<3 days) reduced mortality, intubation needs, and ICU stay, along with improvements in inflammatory markers.", "population_specificity": "Critically ill COVID-19 patients admitted to tertiary care centers.", "effective_dosage": "0.3 mL intradermal Mw for 3 consecutive days.", "study_duration": "3 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:26.447482+00:00"}
{"study_id": 102822, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the clinical efficacy and safety of simvastatin in patients with liver cirrhosis, not specifically focusing on Alanine.", "results_summary": "The study found that simvastatin significantly reduced mortality rates and fatal bleeding in cirrhotic patients, without significantly elevating alanine aminotransferase (ALT) levels or causing other side effects.", "population_specificity": "Patients with liver cirrhosis", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:26.813215+00:00"}
{"study_id": 102819, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the safety and antitumour activity of zandelisib, a PI3K\u03b4 inhibitor, with continuous or intermittent dosing in patients with relapsed or refractory B-cell malignancy, not specifically Alanine.", "results_summary": "The study found that zandelisib was safe with intermittent dosing, showing low frequency of grade 3 or worse adverse events, including alanine aminotransferase increase in some patients. Antitumour activity was observed across doses, but the study did not focus on Alanine's effects.", "population_specificity": "Patients aged 18+ with relapsed or refractory B-cell malignancy (follicular lymphoma or chronic lymphocytic leukaemia).", "effective_dosage": "Not applicable (study focused on zandelisib, not Alanine).", "study_duration": "Median duration of exposure was 15.2 months (IQR 3.7-21.7).", "interactions": "None mentioned (study did not assess Alanine interactions).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:26.891890+00:00"}
{"study_id": 102820, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the evidence base on liver function test (LFT) assessment in infectious mononucleosis (IM), including the role of alanine transaminase (ALT) as a marker, and the need for abdominal ultrasound in patients with abnormal LFTs.", "results_summary": "The study found that 62% of patients with IM had abnormal alanine transaminase (ALT) levels, with a median time to resolution of 8 weeks. No cases of decompensated liver disease were reported, suggesting that routine LFT monitoring and abdominal ultrasound may not be necessary in immunocompetent patients.", "population_specificity": "Adult and pediatric patients with infectious mononucleosis (IM).", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:27.280391+00:00"}
{"study_id": 102824, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to identify non-invasive biomarkers, including alanine aminotransferase (ALT), for diagnosing NASH and liver fibrosis.", "results_summary": "The study found that ALT, combined with other biomarkers, accurately predicted NASH and liver fibrosis with high sensitivity and specificity, outperforming existing diagnostic methods.", "population_specificity": "250 patients with histologically proven NAFL or NASH, with or without fibrosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:30.075716+00:00"}
{"study_id": 102825, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to characterize metabolic pathways, including the glucose-alanine cycle, in dogs with sepsis to identify potential diagnostic and prognostic biomarkers.", "results_summary": "The study identified alterations in the glucose-alanine cycle among other metabolic pathways in dogs with sepsis, suggesting its potential role as a biomarker. Alanine-related pathways were enriched, but specific efficacy outcomes were not detailed.", "population_specificity": "21 client-owned dogs with sepsis and 20 healthy control dogs.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:32.419349+00:00"}
{"study_id": 102823, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of fenofibrate on liver biochemistries, including alanine aminotransferase (ALT), in patients with primary sclerosing cholangitis (PSC).", "results_summary": "Fenofibrate significantly reduced ALT levels by 52.78% in PSC patients, though other secondary endpoints (Mayo Risk Score and bilirubin levels) were not met. The primary endpoint (reduction >50% or normalization of ALP) was achieved in 66.7% of fenofibrate-treated patients.", "population_specificity": "30 PSC patients (19 female, 11 male, mean age 40.2 \u00b1 9.2 years) already on Ursodeoxycholic acid.", "effective_dosage": "200 mg fenofibrate once daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:34.433125+00:00"}
{"study_id": 102826, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the efficacy and safety of cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma, not specifically focused on Alanine.", "results_summary": "The study found that cabozantinib plus atezolizumab improved progression-free survival compared to sorafenib but did not show a significant difference in overall survival. Adverse events, including alanine aminotransferase increase, were more common in the combination treatment group.", "population_specificity": "Patients aged 18 or older with advanced hepatocellular carcinoma, not previously treated with systemic anticancer therapy, and with Child-Pugh class A liver function.", "effective_dosage": "Not applicable (study focused on cabozantinib and atezolizumab, not Alanine).", "study_duration": "Median follow-up was 15.8 months for progression-free survival and 13.3 months for overall survival.", "interactions": "None mentioned (study did not focus on Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:35.885135+00:00"}
{"study_id": 102829, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effects of endoscopic bariatric and metabolic therapies (EBMTs) on non-alcoholic fatty liver disease (NAFLD) in patients with obesity, including the impact on liver parameters such as alanine transaminase.", "results_summary": "EBMTs significantly reduced serum levels of alanine transaminase, improved liver steatosis, and enhanced metabolic parameters like insulin resistance and lipid profiles in patients with NAFLD and obesity.", "population_specificity": "Patients with obesity and NAFLD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:36.019360+00:00"}
{"study_id": 102830, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of saroglitazar, including its effects on alanine aminotransferase levels, in patients with dyslipidemia.", "results_summary": "Saroglitazar significantly reduced LDL and total cholesterol without adverse effects on serum creatinine, alanine aminotransferase, aspartate aminotransferase, or bodyweight. It was deemed effective and safe for dyslipidemia management.", "population_specificity": "581 adults with dyslipidemia, mean age 40.2\u201362.6 years.", "effective_dosage": "2 mg and 4 mg saroglitazar.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:37.074152+00:00"}
{"study_id": 102827, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the relationship between liver function tests (including alanine aminotransferase, ALT) and major cardiorenal outcomes in type 2 diabetes patients, and the impact of canagliflozin treatment.", "results_summary": "ALT was independently associated with lower cardiovascular outcomes risk, while \u03b3GT and ALP were linked to higher risks. Canagliflozin treatment reduced ALT, AST, and \u03b3GT levels over time and lowered heart failure and renal risk independently of liver function tests.", "population_specificity": "10,142 patients with type 2 diabetes and high cardiovascular risk.", "effective_dosage": "Not specified", "study_duration": "Repeated measurements over follow-up (duration not explicitly stated)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:37.249639+00:00"}
{"study_id": 102831, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the relationship between tepotinib exposure and its efficacy and safety outcomes in NSCLC patients with METex14 skipping alterations.", "results_summary": "Tepotinib showed flat exposure-efficacy and exposure-safety relationships across tested doses (30-1400 mg), with edema being the most frequent adverse event. Concentration-QTc analyses indicated minimal QT interval prolongation at therapeutic and supratherapeutic doses.", "population_specificity": "Non-small cell lung cancer (NSCLC) patients with METex14 skipping alterations.", "effective_dosage": "500 mg/day (therapeutic dose), with analyses including doses from 30-1400 mg.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:38.744784+00:00"}
{"study_id": 102832, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the hepatoprotective effects of Artichoke leaf extract (ALE) on alanine aminotransferase levels in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The meta-analysis of five RCTs showed that ALE significantly reduced alanine aminotransferase levels (SMD: 1.1; 95% CI, 0.79-1.73), indicating a beneficial effect on liver health in NAFLD patients.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:39.695785+00:00"}
{"study_id": 102833, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compile the roles of viral and human enzymes, including proteases, in the context of SARS-CoV-2 infection.", "results_summary": "The abstract highlights that proteases are vital for SARS-CoV-2 infection, focusing on the main protease's role, but does not specifically address Alanine's effects.", "population_specificity": "Not specified (general focus on viral and human enzymes in SARS-CoV-2 infection).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:40.877621+00:00"}
{"study_id": 102835, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the clinical efficacy of laparoscopic surgery versus conventional laparotomy in treating acute cholangitis of severe type (ACST).", "results_summary": "The meta-analysis found that laparoscopic surgery improved treatment efficiency, reduced complication risks, and yielded better outcomes in ACST patients compared to conventional laparotomy.", "population_specificity": "Patients with acute cholangitis of severe type (ACST).", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:44.096440+00:00"}
{"study_id": 102834, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to explore the efficacy and renal safety of tenofovir alafenamide (TAF) treatment in chronic hepatitis B patients after one year.", "results_summary": "Virological suppression was achieved in 83% of patients, with a median decline in hepatitis B virus DNA of 5.18 log IU/mL. ALT normalization occurred in 75.7%, and HBsAg levels decreased significantly, though modest changes in renal function (eGFR and creatinine) were observed.", "population_specificity": "148 chronic hepatitis B patients (42 HBeAg-positive and 106 HBeAg-negative).", "effective_dosage": "Not specified in the abstract.", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:44.754255+00:00"}
{"study_id": 102836, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of a calorie-restricted diet on oxidative/anti-oxidative status in NAFLD patients, including the role of alanine aminotransferase (ALT) as a marker.", "results_summary": "The study found significant reductions in serum ALT levels in the calorie-restricted diet group compared to controls, but no significant changes in oxidative/anti-oxidative markers.", "population_specificity": "60 patients with NAFLD, aged 20-60, BMI 25-35 kg/m\u00b2.", "effective_dosage": "Not specified (calorie-restricted diet intervention).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:46.649682+00:00"}
{"study_id": 102837, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of entecavir (ETV) versus ETV maleate in Chinese patients with chronic hepatitis B (CHB).", "results_summary": "The study found that both ETV and ETV maleate similarly reduced HBV DNA levels in HBeAg-positive CHB patients, with no significant differences in efficacy endpoints such as HBV DNA suppression, HBeAg loss, or ALT normalization. Adverse events were recorded but not detailed in the abstract.", "population_specificity": "Chinese patients with chronic hepatitis B (HBeAg-positive and HBeAg-negative).", "effective_dosage": "0.5 mg/day of ETV or ETV maleate.", "study_duration": "48 weeks initial treatment, followed by extended treatment up to 240 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:47.832717+00:00"}
{"study_id": 102839, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether licogliflozin, by inhibiting sodium-glucose cotransporters 1 and 2, could improve serum alanine aminotransferase levels in patients with NASH.", "results_summary": "Licogliflozin 150 mg significantly reduced serum alanine aminotransferase by 32% compared to placebo, meeting the primary endpoint, while the 30 mg dose did not. Diarrhea was a common but mostly mild adverse effect.", "population_specificity": "107 patients with phenotypic or histologic NASH.", "effective_dosage": "30 mg or 150 mg once daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:48.626641+00:00"}
{"study_id": 102838, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of pyronaridine-artesunate, including its impact on liver enzymes like alanine aminotransferase (ALT), compared to other antimalarial treatments for uncomplicated Plasmodium falciparum malaria.", "results_summary": "Pyronaridine-artesunate was associated with elevated ALT levels (high-certainty evidence) but showed no severe liver injury. It demonstrated high efficacy, with PCR-adjusted treatment failure rates below 5%, and performed comparably or better than other ACTs.", "population_specificity": "Individuals with uncomplicated P. falciparum malaria, including 541 children under five years, across 13 African and five Asian sites.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Follow-up periods included days 28 and 42 post-treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:48.783250+00:00"}
{"study_id": 102840, "supplement_id": 863, "safety_score": "75", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and efficacy of GSK3389404, an antisense oligonucleotide targeting HBV RNA, in reducing viral proteins in patients with chronic HBV infection.", "results_summary": "The study found dose-dependent reductions in HBsAg levels, with an acceptable safety profile, but no clear optimal dosing regimen was identified.", "population_specificity": "Patients with chronic hepatitis B on nucleos(t)ide analogue therapy.", "effective_dosage": "30, 60, 120 mg weekly or 120 mg bi-weekly.", "study_duration": "Until Day 85.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:50.311678+00:00"}
{"study_id": 102842, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effect of a fruit-rich diet (FRD) on liver steatosis, liver enzymes (including alanine aminotransferase (ALT)), insulin resistance, and lipid profile in patients with NAFLD.", "results_summary": "The study found that consuming more than 4 servings of fruits per day exacerbated steatosis, dyslipidemia, and glycemic control in NAFLD patients, with no significant improvement in liver enzymes like ALT.", "population_specificity": "Eighty adults with NAFLD.", "effective_dosage": "At least 4 servings of fruits daily (FRD group) vs. less than 2 servings/day (control group).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:54.170026+00:00"}
{"study_id": 102841, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between clinical laboratory parameters, including alanine aminotransferase (ALT), and fatality in patients with severe fever with thrombocytopenia syndrome (SFTS).", "results_summary": "The study found that alanine aminotransferase (ALT) was not strongly associated with mortality in SFTS patients, unlike other parameters such as viral load, platelet count, and liver function markers. ALT did not show significant standardized mean differences (SMD) in the subgroup analyses.", "population_specificity": "SFTS patients across three countries (over 3300 participants).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:54.466660+00:00"}
{"study_id": 102843, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of semaglutide in improving alanine aminotransferase (ALT) levels and other measures in patients with metabolic-dysfunction associated fatty-liver disease (MAFLD) and/or type-2 diabetes (T2DM).", "results_summary": "Injectable semaglutide (0.4mg/0.5mg once weekly) significantly lowered ALT levels and improved certain radiologic features in MAFLD, though conclusions were limited by the small number of patients evaluated.", "population_specificity": "Patients with MAFLD and/or type-2 diabetes (T2DM).", "effective_dosage": "0.4mg/0.5mg once weekly.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:54.883067+00:00"}
{"study_id": 102845, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether a combination of amino acids including alanine (SAGAT) could improve mental health outcomes such as fatigue sensation, motivation, and cognitive function.", "results_summary": "The study found no significant differences in primary outcomes (fatigue sensation), but the SAGAT group showed significant improvements in motivation and cognitive function during recovery after mental work compared to placebo.", "population_specificity": "Adults aged 20-65 years with fatigue sensation.", "effective_dosage": "Not specified", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:56.744956+00:00"}
{"study_id": 102844, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers investigated the spectrum of bile duct injury and associated natural history in patients with immune-related hepatitis during treatment with immune checkpoint inhibitors, including the role of alanine aminotransferase levels.", "results_summary": "The study found elevated alanine aminotransferase levels (median 225 U/L) in patients with bile duct injury, indicating liver dysfunction. Clinical jaundice and radiological evidence of bile duct pathology were common, and immunosuppressive treatment had limited efficacy.", "population_specificity": "Patients with bile duct injury during immune checkpoint inhibitor treatment for malignancy.", "effective_dosage": "Not specified", "study_duration": "Median of 6 cycles prior to bile duct injury (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:57.244511+00:00"}
{"study_id": 102847, "supplement_id": 863, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize the role of environmental bacteria, including the cyanobacterial toxin BMAA (\u03b2-N-methylamino-L-alanine), in brain diseases by examining toxicological mechanisms.", "results_summary": "The study found that BMAA and its isomers act through multiple toxicological pathways, including inflammation, oxidative stress, and excitotoxicity, but further research is needed to clarify cocktail effects and intervention targets.", "population_specificity": "Not specified (in vitro and in vivo models referenced).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:57.621309+00:00"}
{"study_id": 102848, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to determine the effects of grape products on liver enzymes, including alanine aminotransferase (ALT), in adults.", "results_summary": "The meta-analysis found no significant change in serum ALT levels (WMD: -2.04; 95% CI: -5.50 to 1.42; P=0.24) following grape product consumption. The findings suggest grape products do not significantly affect liver enzymes, but caution is advised due to the limited number of studies.", "population_specificity": "Adults (291 participants across 8 RCTs)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:59.689501+00:00"}
{"study_id": 102846, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the effects of a customized hypocaloric diet and enhanced physical activity on intrahepatic fat contents and NAFLD progression in patients with metabolic syndrome, including evaluating biochemical parameters such as alanine aminotransferase (ALT).", "results_summary": "The study found that participants with NAFLD and metabolic syndrome showed reduced intrahepatic fat contents and liver stiffness, along with improvements in ALT levels, BMI, insulin, Hb1Ac, diastolic blood pressure, and HDL-cholesterol. Dietary and physical activity interventions also improved energy intake and consumption of fish and legumes.", "population_specificity": "Adults aged 40-60 years from the Balearic Islands and Navarra (Spain) with NAFLD, metabolic syndrome, and a BMI between 27 and 40 kg/m\u00b2.", "effective_dosage": "Not specified", "study_duration": "6 and 12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:00.576930+00:00"}
{"study_id": 102849, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify risk factors, including elevated alanine aminotransferase (ALT) levels, associated with liver-related morbidity and death after HCV cure.", "results_summary": "Elevated ALT and GGT levels post-HCV cure were predictive of adverse liver outcomes, with GGT being the strongest predictor, particularly in combination with cirrhosis. Elevated ALT (AASLD criteria) and standard ALT also predicted hepatic decompensation.", "population_specificity": "6982 patients from the German Hepatitis C Registry with chronic HCV infection, followed for up to 7 years after DAA therapy.", "effective_dosage": "Not specified", "study_duration": "Up to 7 years of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:04.273589+00:00"}
{"study_id": 102851, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not assess Alanine; it focused on comparing the long-term effectiveness and safety of SGLT2 inhibitors (dapagliflozin and empagliflozin) in T2D patients.", "results_summary": "The study did not evaluate Alanine; it found that both dapagliflozin and empagliflozin effectively lowered blood glucose, reduced body weight, and stabilized blood pressure in T2D patients over 36 months.", "population_specificity": "Patients with type 2 diabetes (T2D)", "effective_dosage": "Not mentioned (study compared different doses of SGLT2 inhibitors, not Alanine)", "study_duration": "36 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:05.612369+00:00"}
{"study_id": 102850, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of curcumin on liver ultrasonographic morphology and its effectiveness as an adjuvant treatment for NAFLD.", "results_summary": "Curcumin improved NAFLD severity and liver steatosis resolution, reduced liver enzymes (AST, ALT), total cholesterol, and BMI in participants with NAFLD.", "population_specificity": "Participants with NAFLD (1028 total across 16 RCTs).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:05.637768+00:00"}
{"study_id": 102852, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of compound glycyrrhizin (CG) in improving liver function and treating liver cancer, with a focus on its impact on alanine aminotransferase (ALT) levels.", "results_summary": "CG treatment significantly improved ALT, AST, TBIL, and ALB levels in liver cancer patients, showing higher efficacy than the control group. Adverse reactions, though slightly higher, were manageable.", "population_specificity": "Patients with primary and metastatic liver cancer.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:05.961471+00:00"}
{"study_id": 102853, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of an alanine aminotransferase-based algorithm in determining eligibility for tenofovir disoproxil fumarate to prevent mother-to-child transmission of HBV.", "results_summary": "The study found that an immunoglobulin-free strategy using an HBeAg rapid test and alanine aminotransferase-based algorithm effectively prevented HBV transmission when tenofovir was initiated at least 4 weeks before birth, with a 1% HBV infection rate in infants.", "population_specificity": "Pregnant women positive for HBsAg, aged 18 or older, excluding those with HCV/HIV coinfection, severe gravid disease, or low creatinine clearance.", "effective_dosage": "300 mg of tenofovir disoproxil fumarate orally once daily.", "study_duration": "From the 24th week of gestation until 6 weeks postpartum.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:08.628655+00:00"}
{"study_id": 102855, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to investigate the effect of berberis aristate and Silybum marianum on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in adults.", "results_summary": "The study found no statistically significant change in ALT or AST levels following BBR-silymarin consumption. The results suggest no significant reduction in liver enzymes from the supplement.", "population_specificity": "Adults (549 participants across 5 trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:09.118484+00:00"}
{"study_id": 102856, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the protective effect of nano-curcumin (NC) on inflammatory biomarkers, endothelial function, oxidative stress indices, biochemical factors, nutritional status, and clinical outcomes in patients with sepsis, not Alanine.", "results_summary": "The abstract does not mention Alanine or its effects.", "population_specificity": "ICU-admitted patients with sepsis.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "10 days (for nano-curcumin, not Alanine).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:09.539644+00:00"}
{"study_id": 102854, "supplement_id": 863, "safety_score": "80", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and clinical activity of olutasidenib in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation.", "results_summary": "Olutasidenib was well tolerated with no dose-limiting toxicities observed. Disease control rate was 48%, with 8% achieving partial response and 32% stable disease for at least 4 months. Grade 3-4 adverse events included increased alanine aminotransferase and aspartate aminotransferase in 12% of patients.", "population_specificity": "Patients (\u226518 years) with relapsed/refractory IDH1R132X-mutated gliomas.", "effective_dosage": "150 mg orally twice daily.", "study_duration": "Continuous 28-day cycles (median follow-up 15.1 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:09.846357+00:00"}
{"study_id": 102858, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it focuses on radiation segmentectomy for treating unresectable early-stage hepatocellular carcinoma.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Adults with solitary hepatocellular carcinoma unsuitable for ablation.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:12.881819+00:00"}
{"study_id": 102857, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to examine factors predisposing hospitalized COVID-19 patients to falls, including the role of alanine aminotransferase (ALT) levels.", "results_summary": "The study found that ALT levels were significantly lower in COVID-19 patients who fell compared to those who did not (17.1 vs 33.5 IU/L, P=0.041). However, the study did not investigate alanine as a supplement or its direct effects.", "population_specificity": "Hospitalized COVID-19 patients (median age 75 years, 51.3% male).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:14.320855+00:00"}
{"study_id": 102859, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to assess the efficacy of ursodeoxycholic acid (UDCA) in reducing liver damage markers, including alanine aminotransferase (ALT), in patients with nonalcoholic steatohepatitis (NASH).", "results_summary": "UDCA treatment significantly reduced blood concentrations of ALT and \u03b3-glutamyl transferase (GGT) but had no significant effect on anthropometric characteristics or hepatic histology.", "population_specificity": "Patients with nonalcoholic steatohepatitis (NASH).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:15.525121+00:00"}
{"study_id": 102860, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop and validate a novel risk stratification model (ABC model) for hepatic decompensation in compensated advanced chronic liver disease (cACLD) patients, incorporating alanine aminotransferase (ALT) as one of the independent risk factors.", "results_summary": "The study found that ALT, along with other factors like liver stiffness measurement, platelet count, albumin, and varices, was an independent predictor of hepatic decompensation risk in cACLD patients. The ABC model, which includes ALT, demonstrated high predictive accuracy for decompensation risk (3-year tAUC of 0.851 in the training cohort and 0.843 in the validation cohort).", "population_specificity": "Patients with compensated advanced chronic liver disease (cACLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:16.983007+00:00"}
{"study_id": 102863, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on the safety and efficacy of a liver-tropic adeno-associated virus vector (BBM-H901) for haemophilia B gene therapy.", "results_summary": "The study does not provide any results related to Alanine.", "population_specificity": "Not applicable (study focused on haemophilia B patients).", "effective_dosage": "Not applicable.", "study_duration": "Not applicable.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:17.790564+00:00"}
{"study_id": 102861, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the clinical efficacy and tolerability of onasemnogene abeparvovec in SMA type 1 patients, including those previously treated with nusinersen.", "results_summary": "The study found significant improvements in motor function (CHOP-INTEND scores) for patients switching from nusinersen to onasemnogene abeparvovec, with two poor responders to nusinersen showing notable improvement. No unknown adverse events occurred, though one case of thrombocytopenia was reported.", "population_specificity": "9 SMA type 1 patients aged 1.7-48 months, including 7 on stable nusinersen therapy.", "effective_dosage": "Not specified", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:19.239823+00:00"}
{"study_id": 102862, "supplement_id": 863, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the risk of drug-induced liver injury (DILI) associated with antirheumatic drugs, including the role of alanine aminotransferase (ALT) elevation as a potential indicator.", "results_summary": "The study highlights that ALT elevation in clinical trials may predict more severe liver injury, with biologic and targeted synthetic DMARDs posing lower risks but still capable of causing liver damage. Pre-existing conditions like NAFLD, diabetes, and obesity may exacerbate DILI.", "population_specificity": "Patients with rheumatoid arthritis or other conditions treated with antirheumatic drugs.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:19.375004+00:00"}
{"study_id": 102864, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of diammonium glycyrrhizinate (DG) in treating chronic hepatitis B (CHB) by analyzing its effects on liver-function recovery and viral suppression.", "results_summary": "DG effectively reduced liver-function markers (ALT, AST, TBIL) and showed better efficacy than conventional treatment within the first 3 months. Different DG dosage forms varied in effectiveness, with capsules performing comparably to other drugs, while enteric-coated capsules and injections were less effective.", "population_specificity": "Patients with chronic hepatitis B (CHB).", "effective_dosage": "Not specified.", "study_duration": "Up to 3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:20.031609+00:00"}
{"study_id": 102866, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the clinical significance of plasma-free amino acids, including alanine, in predicting overall survival in NSCLC patients treated with PD-1 inhibitors.", "results_summary": "Higher plasma concentrations of alanine were significantly correlated with better overall survival in NSCLC patients receiving PD-1 inhibitors, suggesting a potential role in immune response modulation. The study also identified a multivariate model combining amino acids and metabolites for patient stratification.", "population_specificity": "53 patients with non-small cell lung cancer (NSCLC) before treatment with PD-1 inhibitors.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:24.042792+00:00"}
{"study_id": 102865, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of combination therapy (tofogliflozin and pioglitazone) on hepatic steatosis and diabetes mellitus in patients with NAFLD and T2DM, including its impact on alanine aminotransferase levels.", "results_summary": "The combination therapy improved glycated hemoglobin, hepatic steatosis, hepatic stiffness, and alanine aminotransferase levels compared to monotherapy. It also reduced weight gain and showed cardioprotective effects.", "population_specificity": "Patients with NAFLD, T2DM, and a hepatic fat fraction of \u226510%.", "effective_dosage": "20 mg tofogliflozin or 15-30 mg pioglitazone orally, once daily.", "study_duration": "24 weeks of monotherapy followed by 24 weeks of combination therapy (total 48 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:24.358261+00:00"}
{"study_id": 102867, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess drug-induced liver injury (DILI) in COVID-19 patients using the RUCAM method, focusing on clinical features and causality of liver test abnormalities.", "results_summary": "The study identified DILI in COVID-19 patients, primarily caused by antiviral drugs, with hepatocellular injury being more common than cholestatic or mixed injury. Outcomes were mostly favorable, though fatal in 19 cases.", "population_specificity": "COVID-19 patients with suspected drug-induced liver injury from countries including China, India, Japan, Montenegro, and Spain.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:25.326018+00:00"}
{"study_id": 102869, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it focuses on pembrolizumab for NSCLC patients with poor performance status and PD-L1 expression \u226550%.", "results_summary": "The study does not report findings related to Alanine; it discusses pembrolizumab's efficacy and safety in NSCLC patients.", "population_specificity": "NSCLC patients with poor performance status (PS 2-3) and PD-L1 expression \u226550%.", "effective_dosage": "Not mentioned (study does not involve Alanine).", "study_duration": "Not mentioned (study does not involve Alanine).", "interactions": "None mentioned (study does not involve Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:27.017708+00:00"}
{"study_id": 102868, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of direct-acting antiviral (DAA) regimens, including the role of elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as predictors for non-sustained virologic response (non-SVR) in chronic hepatitis C patients.", "results_summary": "Elevated ALT and AST at baseline were specifically associated with non-SVR in patients with genotype 3 and 6 infections, with baseline AST being the best predictor for SVR in these genotypes. The study did not focus on alanine's direct effects but noted its association with treatment outcomes.", "population_specificity": "Chronic hepatitis C patients in Guangdong, China, with multiple genotypes (1, 2, 3, 6, and untyped).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:28.612663+00:00"}
{"study_id": 102871, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to derive contextual comparator data for clinical trials of intestinal bile acid transport inhibitors in Alagille syndrome (ALGS) by analyzing real-world data from a natural history cohort.", "results_summary": "The study found no significant changes in alanine aminotransferase levels over a 2-year follow-up in the ALGS natural history cohort, while pruritus significantly decreased and platelet count dropped significantly.", "population_specificity": "Children with cholestasis and Alagille syndrome (ALGS) with their native liver.", "effective_dosage": "Not specified", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:28.782968+00:00"}
{"study_id": 102870, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of Lenvatinib (LEN) as a first-line treatment for patients with hepatocellular carcinoma (HCC) at BCLC substage B2, not Alanine.", "results_summary": "The study found that LEN had a 1-year survival rate of 71.0%, median overall survival of 17.0 months, and common adverse events included fatigue, hypertension, and anorexia. No results related to Alanine were reported.", "population_specificity": "Patients with HCC at BCLC substage B2 and preserved hepatic function.", "effective_dosage": "Not mentioned (study focused on LEN, not Alanine).", "study_duration": "2-year enrollment period with a 10-month follow-up.", "interactions": "None mentioned (study focused on LEN, not Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:30.144020+00:00"}
{"study_id": 102872, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study evaluated the efficacy and safety of anlotinib plus TQB2450 in advanced biliary tract cancers, not specifically Alanine.", "results_summary": "The study found that anlotinib plus TQB2450 showed promising efficacy in advanced BTCs, with an objective response rate of 21.21% and a disease control rate of 72.73%. Adverse events included elevated alanine aminotransferase levels in 6.06% of patients.", "population_specificity": "Patients with advanced biliary tract cancers who had progressed or declined or were ineligible for first-line chemotherapy.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up was 19.68 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:30.230984+00:00"}
{"study_id": 102875, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to investigate whether reducing sedentary behavior improves cardiometabolic biomarkers in adults with metabolic syndrome, not specifically related to Alanine.", "results_summary": "The intervention group reduced sedentary behavior by 50 min/day and showed significant improvements in fasting insulin, insulin resistance, and other cardiometabolic biomarkers compared to the control group.", "population_specificity": "Sedentary middle-aged adults with metabolic syndrome", "effective_dosage": "Not applicable", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:33.485457+00:00"}
{"study_id": 102873, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to explore the frequencies and diagnostic predictors of priority infections causing persistent fever in tropical regions, with elevated alanine aminotransferase levels identified as a predictor for enteric fever and rickettsiosis.", "results_summary": "Elevated alanine aminotransferase levels were found to have a positive likelihood ratio \u22653 for enteric fever and rickettsiosis, indicating its potential diagnostic utility for these infections. The study did not focus on alanine as a supplement or therapeutic agent.", "population_specificity": "Patients aged 5 years or older with persistent fever in tropical regions (Sudan, DRC, Nepal, Cambodia).", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:34.162856+00:00"}
{"study_id": 102874, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the influence of a ketogenic diet (KD) on serum leptin, chemerin, and resistin levels in children with drug-resistant epilepsy (DRE), not specifically focusing on alanine.", "results_summary": "The study found that serum levels of leptin and chemerin were significantly lower, and resistin higher, in the KD group compared to those treated with valproic acid (VPA) and controls. Alanine aminotransferase was measured but results specific to alanine were not highlighted.", "population_specificity": "72 children aged 3-9 years, divided into groups with DRE treated with KD, DRE treated with VPA, and a control group.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:35.999245+00:00"}
{"study_id": 102877, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to analyze published cases of autoimmune hepatitis (AIH) following COVID-19 vaccination, including characteristic findings, treatment, and outcomes.", "results_summary": "The study found 32 cases of AIH-like syndromes post-vaccination, with jaundice as the most common symptom (81%). Most patients (97%) showed improvement or complete resolution with steroid treatment, though one patient died.", "population_specificity": "Individuals who developed AIH following COVID-19 vaccination.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:37.465672+00:00"}
{"study_id": 102876, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the frequency of liver blood tests, including alanine aminotransferase (ALT), in primary care populations to assess their potential for opportunistic screening of liver disease.", "results_summary": "The study found that ALT testing increased from 2% to 33% over 18 years, with values varying by age and sex, particularly in males, where the upper normal range decreased with age. The reduction in AST testing limited the use of non-invasive liver marker algorithms, suggesting a need for alternative approaches.", "population_specificity": "Adult patients in Wales (2,145,178 individuals) from 2000-2017.", "effective_dosage": "Not available", "study_duration": "18-year study period", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:38.058178+00:00"}
{"study_id": 102880, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and adverse events of favipiravir in patients with COVID-19, not specifically Alanine.", "results_summary": "The study did not focus on Alanine's effects but noted increased alanine aminotransferase as an adverse event of favipiravir.", "population_specificity": "Hospitalized and non-hospitalized patients with COVID-19.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Not mentioned for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:38.759123+00:00"}
{"study_id": 102878, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to develop and validate a score (SAFE) to assess liver fibrosis in NAFLD patients using widely available variables, including alanine aminotransferase.", "results_summary": "The SAFE score, incorporating alanine aminotransferase among other variables, effectively distinguished liver fibrosis stages (\u2265F2 vs. F0/1) with high accuracy (AUC \u22650.80) and strong negative predictive values (88%-92%). Higher SAFE scores correlated with shorter long-term survival in NAFLD patients.", "population_specificity": "Patients with biopsy-proven NAFLD from clinical studies and NHANES III participants.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:39.010052+00:00"}
{"study_id": 102879, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the incidence of hepatotoxicity, including elevated alanine aminotransferase (ALT), among cancer patients receiving systemic therapy with and without immune checkpoint blockade (ICB).", "results_summary": "The study found that adding ICB significantly increased the incidence of elevated ALT (any grade: OR, 2.01; grade 3-5: OR, 2.40), indicating higher hepatotoxicity risk. No significant heterogeneity was observed among ICB mechanisms for hepatitis outcomes.", "population_specificity": "Cancer patients participating in 43 phase 3 randomized controlled trials (28,905 participants).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:40.084060+00:00"}
{"study_id": 102882, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the glycemic index (GI) and factors predicting individual glucose response to a new complete nutrition drink containing retrograded starch.", "results_summary": "The study found that the complete nutrition drink had a low GI (48.2 \u00b1 10.4 and 46.7 \u00b1 12.7 with glucose and white bread as references, respectively), but individual glucose responses varied widely (GI: 7-149).", "population_specificity": "Eighteen healthy volunteers with fasting plasma glucose (FPG) < 100 mg/dl.", "effective_dosage": "Not specified", "study_duration": "Single administration with 14-day wash-out intervals between interventions", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:43.558235+00:00"}
{"study_id": 102883, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare clinical and pathologic characteristics between AFP-positive and AFP-negative HCC patients, including the role of alanine aminotransferase (ALT) as a biomarker.", "results_summary": "The study found that HCC patients with high serum AFP levels also had elevated ALT levels, among other biomarkers, suggesting a potential association between AFP status and liver function markers like ALT.", "population_specificity": "HCC patients from Eastern and Southern China, including those with decompensated hepatic cirrhosis, chronic hepatitis B, and HBV asymptomatic carriers.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:45.421642+00:00"}
{"study_id": 102881, "supplement_id": 863, "safety_score": "65", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary anticancer activity of eftozanermin alfa (eftoza) in patients with advanced solid tumors.", "results_summary": "The study found that eftoza had acceptable safety, with common adverse events including increased alanine aminotransferase and aspartate aminotransferase levels, nausea, and fatigue. Preliminary anticancer activity was observed, with partial responses in some patients, and pharmacodynamic effects were confirmed in circulation and tumor tissue.", "population_specificity": "Patients with advanced solid tumors (colorectal cancer and pancreatic cancer subgroups in the dose-optimization cohort).", "effective_dosage": "2.5-15 mg/kg intravenously on day 1 or day 1/day 8 every 21 days (dose-escalation phase); 1.25-7.5 mg/kg once-weekly (dose-optimization phase).", "study_duration": "Not explicitly stated, but follow-up included the first treatment cycle for DLT evaluation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:46.647258+00:00"}
{"study_id": 102887, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the safety, tolerability, and pharmacokinetics of rezafungin after subcutaneous administration in healthy adults.", "results_summary": "The study reported increased alanine aminotransferase and sinus bradycardia as common adverse events, but these were generally mild to moderate and not rezafungin-related. The study was terminated early due to concerns about injection site reactions, but no predetermined halting criteria were met.", "population_specificity": "Healthy adults", "effective_dosage": "Single doses of 1, 10, 30, 60, 100, or 200 mg", "study_duration": "Single-dose administration", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:48.330783+00:00"}
{"study_id": 102885, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the diagnostic accuracy of non-invasive methods, including alanine aminotransferase (ALT), with liver biopsy for detecting and staging NAFLD in obese individuals undergoing bariatric surgery.", "results_summary": "The study found that ALT, as part of the HAIR score, had an accuracy of 40.23% for detecting steatohepatitis, which was lower compared to other markers like APRI and NFS for advanced fibrosis. Liver biopsy remained the most accurate and safe method for diagnosing NAFLD in this population.", "population_specificity": "Obese individuals undergoing bariatric surgery (87.5% female, mean age 34.9\u00b19.7 years).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:48.536118+00:00"}
{"study_id": 102884, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare real-world outcomes of tenofovir alafenamide (TAF) with other first-line regimens (TDF and entecavir) for chronic hepatitis B (CHB), focusing on efficacy and safety.", "results_summary": "At 24 months, TAF showed superior efficacy with a higher percentage of patients achieving HBV DNA suppression (93% vs. 86%) and normalized ALT levels (66% vs. 56%) compared to TDF, while maintaining stable eGFR. However, a higher percentage of patients with eGFR <60 ml/min/1.7 m\u00b2 was noted in the TAF group.", "population_specificity": "Patients with chronic hepatitis B (CHB), mean age 52, 72% hepatitis B e antigen-negative.", "effective_dosage": "Not specified", "study_duration": "24 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:49.022439+00:00"}
{"study_id": 102888, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the prevalence and associated factors of liver steatosis and advanced fibrosis in HIV-monoinfected patients at risk of NAFLD.", "results_summary": "The study found that steatosis was present in two-thirds of the HIV-monoinfected patients at risk of NAFLD, and around 10% had advanced fibrosis. The CAP technique was deemed accurate for screening steatosis in this population.", "population_specificity": "HIV-monoinfected patients, nonexcessive drinkers with metabolic syndrome, and/or persistently elevated liver enzymes, and/or clinical lipodystrophy.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:49.232175+00:00"}
{"study_id": 102886, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of sebelipase alfa (a form of alanine) in patients with lysosomal acid lipase deficiency (LAL-D).", "results_summary": "The study found sustained improvements in liver and lipid parameters, including reduced ALT and AST levels, improved liver and spleen volumes, and favorable changes in cholesterol levels. Infusion-associated reactions were mild or moderate, and the treatment was generally well tolerated.", "population_specificity": "Patients >8 months of age diagnosed with LAL-D.", "effective_dosage": "1.0 mg/kg every other week (qow), with possible escalation to 3.0 mg/kg qow or weekly, or reduction to 0.35 mg/kg qow for tolerability.", "study_duration": "Up to 144 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:50.281071+00:00"}
{"study_id": 102889, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the efficacy and safety of tofacitinib in refractory polyarticular course juvenile idiopathic arthritis (JIA) patients, not specifically Alanine.", "results_summary": "The study found significant improvement in disease activity scores (JADAS 27) in most JIA subtypes, with 70.4% of cases achieving inactive disease at 24 weeks. Side effects like elevated alanine aminotransferase (ALT) were noted but improved over time.", "population_specificity": "Refractory polyarticular course JIA patients (n=27).", "effective_dosage": "Recommended doses of tofacitinib (specific amounts not detailed in abstract).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:53.729386+00:00"}
{"study_id": 102890, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the prevalence, clinical patterns, and risk factors for tigecycline-induced liver injury, with a focus on abnormal baseline alanine aminotransferase levels as a risk factor.", "results_summary": "The study found a 10.3% prevalence of tigecycline-induced liver injury, primarily cholestatic and mild in severity. Abnormal baseline alanine aminotransferase levels, ICU admission, and longer treatment duration were identified as independent risk factors.", "population_specificity": "Inpatients receiving intravenous tigecycline for \u22657 days.", "effective_dosage": "Not specified (intravenous tigecycline).", "study_duration": "\u22657 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:55.677195+00:00"}
{"study_id": 102891, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates pembrolizumab versus chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.", "results_summary": "The study does not report findings specific to Alanine; it discusses adverse events like increased alanine aminotransferase but does not analyze Alanine's effects.", "population_specificity": "Patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.", "effective_dosage": "Not applicable (study does not focus on Alanine).", "study_duration": "Not applicable (study does not focus on Alanine).", "interactions": "None mentioned (study does not focus on Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:56.237687+00:00"}
{"study_id": 102892, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of Camelina sativa oil (CSO), a source of omega-3 fatty acids and antioxidants, on liver enzymes (including alanine aminotransferase, ALT), lipid profile, and other metabolic markers in NAFLD patients.", "results_summary": "CSO supplementation significantly improved ALT levels, lipid profile (except HDL-c), anthropometric indices (except hip and neck circumference), and adiponectin in NAFLD patients compared to placebo. No significant changes were observed in other liver enzymes or HDL-c.", "population_specificity": "46 patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:58.450902+00:00"}
{"study_id": 102893, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the relationship between quantitative hepatitis B core antibody (qAnti-HBc) and hepatic histological inflammation in chronic hepatitis B (CHB) patients with normal or mildly elevated alanine transaminase (NMALT) levels.", "results_summary": "The study found that qAnti-HBc was positively associated with liver inflammation in treatment-naive CHB patients, with a 56% increased risk of moderate to severe inflammation per standard deviation increase in qAnti-HBc. A significant threshold effect was observed at 4.5 log.", "population_specificity": "Treatment-naive chronic hepatitis B (CHB) patients with normal or mildly elevated alanine transaminase (NMALT) levels from 34 Chinese hospitals.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:59.379420+00:00"}
{"study_id": 102895, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to explore the efficacy, risk factors, safety, and persistence of teriflunomide in relapsing-remitting multiple sclerosis (RRMS) patients, not specifically Alanine.", "results_summary": "The study found that teriflunomide was effective in reducing relapse rates and maintaining stable disability scores in RRMS patients, with common adverse events including ALT elevation (related to Alanine aminotransferase).", "population_specificity": "Relapsing-remitting multiple sclerosis (RRMS) patients, primarily treatment-na\u00efve.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Follow-up at 6, 12, and 24 months after teriflunomide initiation.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:59.435843+00:00"}
{"study_id": 102896, "supplement_id": 863, "safety_score": "90", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to determine whether monotherapy with AnluoHuaxian pill (AHP) improves liver histology in chronic hepatitis B (CHB) patients with alanine aminotransferase (ALT) levels less than 2 times the upper limit of normal and early liver fibrosis.", "results_summary": "The study found that AHP significantly improved liver fibrosis compared to placebo, with higher rates of histologic improvement (37.7% vs. 19.5%) and reduced liver stiffness. No serious side effects were reported in the AHP group.", "population_specificity": "CHB patients with ALT<2ULN and early liver fibrosis (F \u2264 2).", "effective_dosage": "Not specified in the abstract.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:01.001162+00:00"}
{"study_id": 102894, "supplement_id": 863, "safety_score": "75", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and preliminary efficacy of sabizabulin, including its impact on alanine aminotransferase levels, in men with metastatic castration-resistant prostate cancer (mCRPC).", "results_summary": "The study found that sabizabulin had a favorable safety profile with predominantly grade 1-2 adverse events, including alanine aminotransferase elevations (5.6% grade \u22653). Preliminary efficacy data showed an objective response rate of 20.7% in patients with measurable disease and a median radiographic progression-free survival of 11.4 months.", "population_specificity": "Men with metastatic castration-resistant prostate cancer (mCRPC), including those with prior androgen receptor-targeting therapy and no prior chemotherapy.", "effective_dosage": "63 mg/day (recommended phase II dose).", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:01.647910+00:00"}
{"study_id": 102899, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to identify the recommended dose for expansion/maximum tolerated dose of IDH305, a mutant-selective IDH1 inhibitor, in patients with IDH1-mutated advanced malignancies.", "results_summary": "IDH305 showed rapid absorption and target engagement but was halted prematurely due to a potentially narrow therapeutic window, preventing declaration of a recommended phase 2 dose.", "population_specificity": "41 patients with IDH1-mutated advanced malignancies.", "effective_dosage": "75-750 mg twice daily.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:04.981151+00:00"}
{"study_id": 102897, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of vupanorsen (a drug targeting ANGPTL3) in reducing non-HDL-C and other lipid parameters in adults with elevated non-HDL-C and triglycerides on statin therapy.", "results_summary": "Vupanorsen significantly reduced non-HDL-C (22.0% to 27.7% decrease) and other lipid parameters, but higher doses were associated with increased injection site reactions, liver enzyme elevations, and hepatic fat fraction.", "population_specificity": "Adults with non-HDL-C \u2265100 mg/dL and triglycerides 150-500 mg/dL on statin therapy (median age 64, 44% female).", "effective_dosage": "60, 80, 120, or 160 mg SC every 2 weeks; or 80, 120, or 160 mg SC every 4 weeks.", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:05.293186+00:00"}
{"study_id": 102898, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the efficacy of plasma exchange (PE) alone versus combined double plasma molecular absorption system (DPMAS + PE) in treating acute-on-chronic liver failure (ACLF), including effects on alanine aminotransferase (ALT) levels.", "results_summary": "The study found that DPMAS + PE significantly reduced ALT levels compared to PE alone, indicating improved liver function. However, no significant changes were observed in other markers like TBIL, ALB, Cr, or PLT.", "population_specificity": "Patients with acute-on-chronic liver failure (ACLF).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:06.385757+00:00"}
{"study_id": 102900, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the efficacy and application value of plasma exchange as an adjuvant therapy in children with hemophagocytic syndrome (HPS), not specifically related to Alanine.", "results_summary": "The study found that plasma exchange improved clinical symptoms, some laboratory markers, and reduced PICU stay duration in children with severe HPS, but it did not assess Alanine.", "population_specificity": "Children with severe hemophagocytic syndrome (HPS) treated in a pediatric intensive care unit (PICU).", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:07.066549+00:00"}
{"study_id": 102902, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to evaluate the feasibility and safety of solo-surgeon pure laparoscopic donor nephrectomy, not Alanine.", "results_summary": "The study found that solo-surgeon pure laparoscopic donor nephrectomy was technically feasible (100% success rate) but noted intraoperative and postoperative complications, including spleen injury and nausea/vomiting. Most complications were unrelated to the solo-surgery technique.", "population_specificity": "Potential candidates for laparoscopic donor nephrectomy (47 screened, 40 enrolled).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:08.929675+00:00"}
{"study_id": 102901, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine the protective effect of branched-chain amino acids (BCAAs), including alanine, on muscle injury in aerobics athletes after endurance exercise.", "results_summary": "The study found that BCAA supplementation helped reduce blood glucose levels post-exercise, increased lactate dehydrogenase and alanine aminotransferase levels in the intervention group, and suggested that longer exercise durations made BCAA supplementation more effective. Alanine levels decreased in both groups after exercise.", "population_specificity": "32 aerobics athletes (16 in the intervention group, 16 in the control group).", "effective_dosage": "Not specified.", "study_duration": "3 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:09.729133+00:00"}
{"study_id": 102904, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify metabolic biomarkers and pathways, including Alanine metabolism, associated with myopia to understand disease mechanisms and potential therapeutic targets.", "results_summary": "The study found that Alanine, aspartate, and glutamate metabolism was one of the significantly enriched pathways in high myopia, suggesting its potential role in the disease's metabolic profile.", "population_specificity": "Human and animal studies (seven human and two animal studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:10.455696+00:00"}
{"study_id": 102903, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of lenvatinib and sorafenib as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) in chronic hepatitis B patients, focusing on overall survival, progression-free survival, time to progression, and tumor response.", "results_summary": "The study found that lenvatinib had comparable overall survival and progression-free survival to sorafenib but demonstrated significantly longer time to progression and better tumor response rates (higher objective response and disease control rates).", "population_specificity": "132 patients with HBV-related unresectable hepatocellular carcinoma (uHCC).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:10.767119+00:00"}
{"study_id": 102905, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of dapagliflozin in improving liver function parameters and metabolic outcomes in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Dapagliflozin significantly reduced alanine aminotransferase (ALT) and aspartate aminotransaminase (AST) levels, improved insulin resistance (HOMA-IR), and reduced body weight and BMI, but had a non-significant effect on gamma-glutamyl transferase (GGT) and increased total cholesterol.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:14.841935+00:00"}
{"study_id": 102906, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to examine the impact of rosemary leaf powder, including its effect on alanine aminotransferase levels, in patients with nonalcoholic fatty liver disease when combined with a weight loss diet.", "results_summary": "The study found that both the rosemary and placebo groups showed significant improvements in liver function markers and metabolic parameters, but there was no statistically significant difference between the groups, except for homeostasis model assessment of \u03b2-cell dysfunction. The results suggest that the observed changes were primarily due to the weight loss diet and physical activity rather than the rosemary supplement.", "population_specificity": "110 patients with nonalcoholic fatty liver disease", "effective_dosage": "4 g rosemary leaf powder daily", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:15.562392+00:00"}
{"study_id": 102907, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the prevalence of elevated liver chemistries, including alanine aminotransferase (ALT), in hospitalized COVID-19 patients and their association with disease severity and mortality.", "results_summary": "The study found that 70.4% of patients had abnormal ALT levels at admission, which were associated with disease severity and higher mortality risk. Elevated ALT, along with other liver markers, was linked to the need for advanced therapies like vasopressors and mechanical ventilation.", "population_specificity": "3,380 hospitalized COVID-19 patients in the Johns Hopkins Health System.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:15.988598+00:00"}
{"study_id": 102908, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy and safety of DA-2802 (a formulation containing Alanine) versus Viread in patients with chronic hepatitis B (CHB).", "results_summary": "The study found that DA-2802 was effective and safe for treating CHB, with comparable outcomes to Viread. The results suggest DA-2802 is a viable alternative for CHB patients.", "population_specificity": "Patients with chronic hepatitis B (CHB) recruited from 25 hospitals in Korea.", "effective_dosage": "319 mg once daily", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:16.980158+00:00"}
{"study_id": 102911, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to establish links between COSIAM parameters (whole-body muscle mass, muscle protein synthesis, and breakdown) and muscle function in older adults.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects, only mentioning the study's focus on COSIAM parameters and muscle function.", "population_specificity": "37 healthy older adults (21 male, 16 female; age 72 \u00b1 5 years).", "effective_dosage": "Not specified", "study_duration": "3-day trial", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:18.806448+00:00"}
{"study_id": 102912, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of konjaku flour (KF) supplementation on treating obesity and regulating intestinal microbiota in obese adults.", "results_summary": "KF significantly reduced BMI, fat mass, blood glucose, blood lipid levels, and improved hepatic function, while also regulating intestinal microbiota structure. The results suggest KF has positive effects on obesity management.", "population_specificity": "Obese adults aged 25-35 with BMI \u226528 kg/m\u00b2.", "effective_dosage": "Not specified", "study_duration": "5 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:19.132811+00:00"}
{"study_id": 102909, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers reviewed the efficacy and safety of tenofovir disoproxil fumarate (TDF) to prevent HBV mother-to-child transmission and discussed changes in maternal viral markers, including alanine aminotransferase (ALT), postpartum.", "results_summary": "The study found that TDF is effective in preventing HBV vertical transmission but noted potential immune-mediated flares post-TDF withdrawal. Changes in ALT levels were discussed as part of maternal viral marker monitoring.", "population_specificity": "Pregnant women with high HBV viraemia (HBV-DNA >200,000 IU/ml) and their infants.", "effective_dosage": "Not specified for alanine aminotransferase (ALT).", "study_duration": "Third trimester of pregnancy through postpartum follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:19.444419+00:00"}
{"study_id": 102910, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the efficacy and safety of CDK4/6 inhibitors combined with neoadjuvant endocrine treatment (NET) compared to NET or neoadjuvant chemotherapy (NACT) alone in ER+/HER2- early breast cancer patients, with a mention of elevated alanine aminotransferase (ALT) levels as an adverse effect.", "results_summary": "The study found that CDK4/6 inhibitors plus NET increased the complete cell cycle arrest (CCCA) rate but did not significantly improve other outcomes like PEPI-0 rate, pCR rate, ORR, or DCR. Elevated ALT levels were noted as a grade 3/4 adverse effect.", "population_specificity": "Patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) early breast cancer (EBC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:20.830877+00:00"}
{"study_id": 102913, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, not specifically focused on Alanine.", "results_summary": "The study found that valoctocogene roxaparvovec increased factor VIII activity levels and reduced bleeding and factor VIII concentrate use, but did not specifically report on Alanine's effects.", "population_specificity": "Men with severe hemophilia A (factor VIII level \u22641 IU/dL) without preexisting anti-AAV5 antibodies or factor VIII inhibitor history.", "effective_dosage": "Single infusion of 6\u00d710^13 vg/kg.", "study_duration": "Follow-up of more than 51 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:25.019819+00:00"}
{"study_id": 102914, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were investigating the combination of nivolumab and cabozantinib in treating recurrent endometrial cancer, not specifically studying Alanine.", "results_summary": "The study found elevated alanine aminotransferase (42%) as a common treatment-related adverse event in Arm A, but did not focus on Alanine's effects.", "population_specificity": "Women with recurrent endometrial cancer, including immunotherapy-na\u00efve and immunotherapy-pretreated patients.", "effective_dosage": "Not mentioned (study focused on nivolumab and cabozantinib, not Alanine).", "study_duration": "Not specified for Alanine (study duration was based on treatment arms).", "interactions": "None mentioned (study did not assess Alanine interactions).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:25.623393+00:00"}
{"study_id": 102915, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and early outcomes of autologous bone marrow mononuclear cell infusion for liver cirrhosis due to biliary atresia, including monitoring alanine aminotransferase levels.", "results_summary": "The study found that autologous BMMNC administration was safe and may maintain or improve liver function, as indicated by monitored serum markers including alanine aminotransferase.", "population_specificity": "Children with liver cirrhosis due to biliary atresia after Kasai operation.", "effective_dosage": "Not specified for alanine; MNC and CD34+ cell counts per kg body weight were 50.1 \u00b1 58.5 \u00d7 10^6 and 1.1 \u00b1 1.3 \u00d7 10^6, respectively.", "study_duration": "12 months (with repeated procedure at 6 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:27.132428+00:00"}
{"study_id": 102919, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the tolerability, safety, and efficacy of vorolanib when combined with checkpoint inhibitors in patients with advanced solid tumors, not specifically Alanine.", "results_summary": "The study reported alanine aminotransferase elevation as a common treatment-related adverse event (n=5), mostly grade 1-2, but did not focus on Alanine's effects.", "population_specificity": "Patients with advanced gastrointestinal or lung cancers.", "effective_dosage": "Not applicable (study focused on vorolanib, not Alanine).", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:28.518660+00:00"}
{"study_id": 102918, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a prognostic model for adult hemophagocytic lymphohistiocytosis (HLH) in China, identifying alanine aminotransferase as one of the independent prognostic factors.", "results_summary": "The study found that alanine aminotransferase was an independent prognostic factor for HLH, contributing to a scoring model that stratified patients into risk groups with varying survival rates. The model demonstrated good predictive accuracy with C-indexes of 0.796 and 0.758 in derivation and validation cohorts.", "population_specificity": "270 newly diagnosed adult HLH patients in China.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:29.625927+00:00"}
{"study_id": 102916, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, anti-tumor activity, and pharmacokinetics of D-0316, a third-generation EGFR-TKI, in patients with locally advanced or metastatic NSCLC harboring the EGFR T790M mutation.", "results_summary": "D-0316 was well tolerated with most adverse events being grade 1 or 2, and demonstrated anti-tumor activity with overall response rates of 33.3% (50 mg) and 45.5% (100 mg), and median progression-free survival of 8.3 and 9.6 months, respectively. The recommended phase II dose was 100 mg.", "population_specificity": "Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR T790M mutation who progressed after prior EGFR-TKI treatment.", "effective_dosage": "25 to 150 mg daily (dose-escalation), 50 and 100 mg daily (dose-expansion).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:29.793950+00:00"}
{"study_id": 102917, "supplement_id": 863, "safety_score": "70", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and feasibility of taminadenant (an A2AR antagonist) with or without spartalizumab in patients with advanced NSCLC, including monitoring for adverse effects like alanine/aspartate aminotransferase increases.", "results_summary": "The study found that taminadenant, alone or combined with spartalizumab, was generally well tolerated, with dose-limiting toxicities including alanine/aspartate aminotransferase increases. Some clinical benefit was observed, including partial and complete responses, though efficacy was not a primary endpoint.", "population_specificity": "Patients with advanced/metastatic NSCLC who had received at least one prior therapy.", "effective_dosage": "Taminadenant (80-640 mg, orally, twice a day) with or without spartalizumab (400 mg, i.v., every 4 weeks).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:31.747910+00:00"}
{"study_id": 102920, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy of stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib in patients with locally recurrent pancreatic cancer, not specifically focused on Alanine.", "results_summary": "The study found that SBRT plus pembrolizumab and trametinib improved median overall survival compared to SBRT plus gemcitabine, with increased alanine aminotransferase or aspartate aminotransferase as common adverse effects. No treatment-related deaths occurred.", "population_specificity": "Patients aged 18+ with histologically confirmed pancreatic ductal adenocarcinoma, mutant KRAS, PD-L1 positive, ECOG performance status 0-1, and documented local recurrence after surgery and chemotherapy.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up was 13.1 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:32.261623+00:00"}
{"study_id": 102921, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to analyze the effectiveness of cell- and G-CSF-based therapies, including their impact on alanine aminotransferase levels, in treating cirrhosis.", "results_summary": "The study found that G-CSF-based and cell-based therapies improved transplantation-free survival rates but demonstrated no obvious improvement in liver injury indicators, including alanine aminotransferase levels.", "population_specificity": "Cirrhosis patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:34.469056+00:00"}
{"study_id": 102922, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether blood concentrations of alanine and other amino acids correlate with neuropsychological performance after acute exercise.", "results_summary": "The study found that amino acid blood concentrations, including alanine, were significantly elevated post-exercise, and cognitive performance improved on specific neuropsychological assessments. A significant interaction effect was observed for the Trail Making Test part-B.", "population_specificity": "Sixty basketball players.", "effective_dosage": "Not available", "study_duration": "Acute (single session)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:35.024927+00:00"}
{"study_id": 102924, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore biomarkers, including alanine aminotransferase (ALAT), to predict drug distribution and optimize antibiotic dosing in critically ill sepsis patients.", "results_summary": "The study suggests that biomarkers like ALAT could help predict drug distribution and guide antibiotic dosing, potentially reducing resistance and mortality, but does not report specific findings on ALAT's direct effects.", "population_specificity": "Critically ill patients with sepsis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:37.139943+00:00"}
{"study_id": 102923, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify significant metabolites and metabolic pathways, including alanine, aspartate, and glutamate metabolism, in women with reproductive failures (EM, RM, RIF) to understand underlying metabolic mechanisms.", "results_summary": "Alanine, aspartate, and glutamate metabolism had the highest impact factor in repeated implantation failure (RIF), suggesting its potential role in reproductive failures. The study highlighted common and distinct metabolic pathways but noted the need for further validation.", "population_specificity": "Women with early miscarriage (EM), recurrent miscarriage (RM), and repeated implantation failure (RIF).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:37.658470+00:00"}
{"study_id": 102925, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether recombinant human growth hormone (rhGH) treatment could improve non-alcoholic fatty liver disease (NAFLD) and related metabolic complications in obese boys.", "results_summary": "The study found that rhGH treatment significantly reduced liver enzymes (ALT, AST, GGT), improved lipid profiles (LDL-C, HDL-C), and decreased inflammatory markers (CRP) and BMI SDS in obese boys with NAFLD, without affecting total cholesterol, triglycerides, or uric acid.", "population_specificity": "44 obese boys with NAFLD (aged 11.76 \u00b1 1.67 years).", "effective_dosage": "Not specified in the abstract.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:39.900233+00:00"}
{"study_id": 102926, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the prognostic risk factors for severe fever with thrombocytopenia syndrome (SFTS), including the role of AST/ALT-ratio, which involves alanine transaminase (ALT).", "results_summary": "The study found that an elevated AST/ALT-ratio was an independent risk factor for poor prognosis in SFTS patients, and ribavirin treatment could decrease this ratio while increasing platelet counts.", "population_specificity": "107 hospitalized patients with SFTSV infection (mean age 60.38 \u00b1 11.29 years, male-to-female ratio 1:1.2).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:39.992833+00:00"}
{"study_id": 102927, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of the Aryl hydrocarbon Receptor (AhR) in modulating COVID-19's inflammatory response, including its regulation of ACE-2 and the Broad neutral Amino acid Transporter 1 (B0AT1), which involves alanine.", "results_summary": "The abstract suggests that AhR may play a significant role in managing COVID-19's inflammatory framework by regulating ACE-2 and B0AT1, but it does not provide specific findings about alanine's effects.", "population_specificity": "Not specified (general discussion of COVID-19 mechanisms).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:41.310325+00:00"}
{"study_id": 102928, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to investigate the efficacy and safety of dapagliflozin in reducing hepatic enzymes and metabolic indicators in adults with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Dapagliflozin significantly reduced hepatic enzymes (alanine transaminase, aspartate transaminase, gamma-glutamyl transferase) and improved metabolic indicators (triglyceride, body weight, HbA1c, fasting plasma glucose) compared to controls, with no difference in adverse events.", "population_specificity": "Adults with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:42.707491+00:00"}
{"study_id": 102929, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to explore the efficacy and safety of enteral ecoimmunonutrition (EEIN), which includes alanine, in patients undergoing hepatectomy.", "results_summary": "The study found that EEIN significantly improved liver function, reduced inflammatory markers, enhanced immune response, and accelerated postoperative gastrointestinal recovery compared to standard enteral or parenteral nutrition.", "population_specificity": "Patients undergoing hepatectomy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:42.964630+00:00"}
{"study_id": 102930, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize the types of HBV flares and associated immune responses, focusing on HBeAg-negative CHB patients, to improve management strategies.", "results_summary": "The abstract discusses HBV flares, their causes, and clinical outcomes but does not specifically evaluate alanine's effects. It highlights the immune response to HBV DNA and antigen surges, leading to ALT level spikes.", "population_specificity": "HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) patients.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:44.153991+00:00"}
{"study_id": 102932, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to examine the effects of ribavirin (RBV) and sofosbuvir (SOF) with silymarin as adjunct therapy on liver function markers, including alanine aminotransferase (ALT).", "results_summary": "The study investigated the impact of DAAs and silymarin on liver function markers like ALT, but specific results regarding ALT were not detailed in the abstract. The abstract mentions examining viral load and genotypes, but outcomes for ALT are unclear.", "population_specificity": "30 patients with hepatitis C virus (HCV), divided into two groups.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:47.169139+00:00"}
{"study_id": 102931, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the clinical activity of abemaciclib in patients with p16ink4A-negative mesothelioma, not specifically Alanine.", "results_summary": "The study found that abemaciclib showed promising clinical activity in p16ink4A-negative mesothelioma patients, with 54% achieving disease control at 12 weeks. Adverse events included increased alanine aminotransferase, but the study did not focus on Alanine's effects.", "population_specificity": "Patients with p16ink4A-negative mesothelioma who had progressed after platinum-based chemotherapy.", "effective_dosage": "Not applicable (study focused on abemaciclib, not Alanine).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:47.320103+00:00"}
{"study_id": 102934, "supplement_id": 863, "safety_score": "80", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether losartan (not alanine) could significantly reduce alanine aminotransferase (ALT) levels in children with NAFLD compared to placebo.", "results_summary": "Losartan did not significantly reduce ALT levels in children with NAFLD compared to placebo, though it did significantly decrease alkaline phosphatase and systolic blood pressure. Adverse events and compliance did not differ between groups.", "population_specificity": "Children aged 8-17 years with histologically confirmed NAFLD, predominantly male (81%) and Hispanic (80%).", "effective_dosage": "100 mg of losartan orally once daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:49.542123+00:00"}
{"study_id": 102933, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers evaluated the safety and efficacy of ledipasvir-sofosbuvir in adolescents with chronic HCV genotype 4 and hematological malignancies undergoing maintenance chemotherapy.", "results_summary": "All 19 patients achieved sustained virologic response (SVR12) with no HCV flares reported. Common adverse events included pyrexia, diarrhea, and headache, but none were considered related to the study drug.", "population_specificity": "Adolescents (ages 12-17) with chronic HCV genotype 4 infection and hematological malignancies undergoing maintenance chemotherapy.", "effective_dosage": "Ledipasvir-sofosbuvir (90 mg/400 mg) once daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:50.366767+00:00"}
{"study_id": 102935, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of aerobic exercise training, with or without diet, in improving liver function, insulin resistance, and lipid profiles in adults with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The meta-analysis found significant improvements in alanine aminotransferase (ALT) levels and other liver function markers, suggesting aerobic exercise, with or without diet, is effective for NAFLD management.", "population_specificity": "Adults with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "4 or more weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:51.149983+00:00"}
{"study_id": 102938, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of ginger supplementation on fatty liver disease, including its impact on alanine aminotransferase (ALT) levels.", "results_summary": "Ginger supplementation significantly reduced serum levels of alanine aminotransferase (ALT) by -2.85 U/L, indicating potential liver function improvement. The study also noted reductions in other markers like AST, TG, and LDL, suggesting broader metabolic benefits.", "population_specificity": "The study included both in-vivo experiments (animal models) and clinical trials (human participants).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:54.200368+00:00"}
{"study_id": 102936, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate severe liver injury cases induced by multityrosine kinase inhibitors (MTKIs) like pazopanib and sunitinib, focusing on alanine aminotransferase (ALT) increases and hyperbilirubinemia.", "results_summary": "The study reported two cases of severe liver injury linked to MTKIs, including grade 4 ALT elevation and hyperbilirubinemia, with one case resulting in fatal liver failure. The findings highlight the unpredictable nature of liver injury in TKI-treated patients and the need for better risk stratification.", "population_specificity": "Metastatic renal cell carcinoma (mRCC) patients treated with pazopanib or sunitinib.", "effective_dosage": "Not specified", "study_duration": "Varied (one case involved 3.5 years of sunitinib treatment, followed by 2 weeks of clarithromycin co-medication).", "interactions": "Clarithromycin co-medication was associated with fatal liver failure in one case.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:55.344718+00:00"}
{"study_id": 102939, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to analyze factors associated with insulin resistance (IR) in chronic HCV-infected patients and evaluate changes in glucose homeostasis after treatment with direct-acting antiviral agents (DAAs).", "results_summary": "The study found that obesity, treatment experience, high serum ALT and triglyceride levels, and advanced hepatic fibrosis were independent factors associated with IR in chronic HCV patients. After DAA treatment, patients with baseline high IR, HCV genotype 1, and treatment experience showed a significant reduction in mean HOMA-IR.", "population_specificity": "Patients with chronic HCV infection (n=704) treated with interferon-free DAAs.", "effective_dosage": "Not specified", "study_duration": "12 weeks post-treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:57.052713+00:00"}
{"study_id": 102937, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the safety and efficacy of temsirolimus in combination with cyclophosphamide and etoposide for treating relapsed/refractory acute lymphoblastic leukemia (ALL) in children and adolescents, not specifically studying Alanine.", "results_summary": "The study found that temsirolimus combined with cyclophosphamide and etoposide had an acceptable safety profile and demonstrated dose-dependent inhibition of the PI3K/mTOR pathway, with a 47% overall response rate and 27% complete response rate. Elevated alanine aminotransferase was noted as a grade 3/4 non-hematologic toxicity in some patients.", "population_specificity": "Children and adolescents with relapsed/refractory ALL.", "effective_dosage": "Temsirolimus doses ranged from 7.5 mg/m\u00b2 to 25 mg/m\u00b2 IV on days 1 and 8, cyclophosphamide 440 mg/m\u00b2 and etoposide 100 mg/m\u00b2 IV daily on days 1-5.", "study_duration": "The intervention was administered over 5 days per cycle (days 1-5 for cyclophosphamide and etoposide, days 1 and 8 for temsirolimus).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:57.214259+00:00"}
{"study_id": 102940, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the levels of alanine and other amino acids in the CSF of patients with MELAS syndrome compared to controls, to understand metabolic imbalances.", "results_summary": "The study found significantly higher CSF levels of alanine in MELAS patients compared to controls, suggesting an upregulation of the lactate-alanine cycle due to metabolic imbalance.", "population_specificity": "Nine adult patients with MELAS syndrome (66.7% females, mean age 35.8 \u00b1 3.2 years) and 19 controls (63.2% females, mean age 42.7 \u00b1 3.8 years).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:57.369257+00:00"}
{"study_id": 102941, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to systematically analyze hematologic toxicity in hematologic malignancies treated with CAR-T cell therapy, including the incidence of alanine transaminase (ALT) increase.", "results_summary": "The study found that ALT increase was one of the adverse effects observed in patients undergoing CAR-T cell therapy, but it did not specifically focus on alanine as a supplement. The incidence of ALT increase was calculated among other hematologic toxicities.", "population_specificity": "Patients with hematologic malignancies undergoing CAR-T cell therapy.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:58.842704+00:00"}
{"study_id": 102942, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify potential metabolic biomarkers and pathways, including alanine metabolism, that might facilitate diagnostic, therapeutic, and prognostic determination in patients with epilepsy (PWE).", "results_summary": "The study found that alanine metabolism was one of the disturbed pathways in both PWE and epileptic models, suggesting its potential role in the pathogenesis of epilepsy. However, the abstract does not specify direct effects or outcomes related to alanine supplementation.", "population_specificity": "Patients with epilepsy (PWE) and animal models of epilepsy.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:59.766632+00:00"}
{"study_id": 102943, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of fish oil plus vitamin D supplementation on biomarkers of hepatocellular damage, including alanine aminotransferase (ALT), in subjects with NAFLD.", "results_summary": "The study found significant reductions in serum ALT levels in the fish oil plus vitamin D and fish oil groups compared to the control group, indicating improved liver health. Additionally, the fish oil plus vitamin D group showed further benefits in reducing insulin levels and inflammation markers.", "population_specificity": "111 subjects with NAFLD, aged 56.0 \u00b1 15.9 years.", "effective_dosage": "3 g/day of capsules providing 2.34 g/day of EPA + DHA + 1680 IU vitamin D.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:03.123518+00:00"}
{"study_id": 102947, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to identify key factors in the pathogenesis of metabolic alterations in obesity using machine learning technology.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects.", "population_specificity": "Patients with obesity (single-center study).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:03.887054+00:00"}
{"study_id": 102944, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and tolerability of perioperative immunotherapy (nivolumab with or without ipilimumab) in patients with resectable hepatocellular carcinoma, not specifically Alanine.", "results_summary": "The study found increased alanine aminotransferase as a common treatment-related adverse event, occurring in 23% of patients on nivolumab and 50% on nivolumab plus ipilimumab. However, the study did not assess Alanine's efficacy or safety as a supplement.", "population_specificity": "Patients with resectable hepatocellular carcinoma.", "effective_dosage": "Not applicable (study focused on immunotherapy, not Alanine).", "study_duration": "Up to 2 years (adjuvant phase).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:05.286326+00:00"}
{"study_id": 102945, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of different nutritional interventions, including those involving alanine (as part of branched-chain amino acids), in improving nutritional indicators and liver function in patients with cirrhosis.", "results_summary": "The study found that enteral nutrition (EN) with branched-chain amino acids was more effective than EN without them, and EN combined with intestinal probiotics appeared superior to other interventions, including PN+EN, in improving outcomes for cirrhosis patients.", "population_specificity": "Patients with liver cirrhosis.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:06.175180+00:00"}
{"study_id": 102946, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize the identification of dengue B-cell epitopes within the envelope (E) protein of dengue, including approaches like mutagenesis/alanine scanning, to guide vaccine design and therapeutic development.", "results_summary": "The abstract highlights the use of alanine scanning among other methods to identify protective linear B-cell epitopes in the dengue E protein, which can inform peptide vaccine constructs and monoclonal antibody therapies. No specific results regarding alanine's effects are detailed.", "population_specificity": "Not specified (focus is on dengue virus research, not human subjects).", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:06.994558+00:00"}
{"study_id": 102948, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to assess the effectiveness and safety of Xiaoyao Powder (XYP) for treating non-alcoholic fatty liver disease (NAFLD), including its impact on serum markers like alanine aminotransferase (ALT).", "results_summary": "XYP, either alone or combined with essential treatment, improved NAFLD by regulating serum markers such as TC, TG, ALT, AST, GGT, and adiponectin. Some adverse events (e.g., flatulence, constipation, diarrhea, rash) were reported in studies involving statins, but others reported no safety concerns.", "population_specificity": "1012 participants with NAFLD across 12 studies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:08.029429+00:00"}
{"study_id": 102949, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to assess the effects of intravenous trehalose on arterial wall inflammation and atherogenesis in human subjects with a history of myocardial infarction and systemic inflammation.", "results_summary": "The study found no significant reduction in arterial wall inflammation or changes in cIMT with trehalose treatment compared to placebo. A significant difference in ALT changes was noted between trehalose and placebo groups, but no other significant effects were observed.", "population_specificity": "15 patients with a history of myocardial infarction and systemic inflammation (C-reactive protein > 2 mg/L).", "effective_dosage": "15 g once weekly (intravenous).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:08.888298+00:00"}
{"study_id": 102950, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study does not focus on Alanine but rather reports a case of congenital CMV infection in a pregnant SLE patient, with Alanine aminotransferase levels mentioned as part of clinical findings.", "results_summary": "The study does not investigate Alanine's effects; elevated Alanine aminotransferase levels were noted as part of SLE exacerbation symptoms, not as a focus of the research.", "population_specificity": "A 19-year-old Japanese primigravida with SLE.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:08.902209+00:00"}
{"study_id": 102951, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, antiviral activity, and pharmacokinetics of JNJ-64530440 (a hepatitis B virus capsid assembly modulator) in patients with chronic hepatitis B.", "results_summary": "JNJ-64530440 demonstrated potent antiviral activity, significantly reducing HBV DNA and RNA levels, and was well tolerated with mild-to-moderate adverse events. The drug's pharmacokinetics in CHB patients were comparable to those in healthy volunteers.", "population_specificity": "Treatment-naive, HBeAg-positive or -negative chronic hepatitis B patients (mean age 43.8 years; 85% male; 70% White).", "effective_dosage": "750 mg once or twice daily.", "study_duration": "28 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:13.294169+00:00"}
{"study_id": 102953, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to assess changes in plasma metabolites, including N-methyl alanine, after HCV clearance with DAAs and their association with liver disease scores in HIV/HCV-coinfected patients with advanced cirrhosis.", "results_summary": "The study found that N-methyl alanine increased after HCV clearance, but its specific effects or associations with liver disease scores were not detailed in the abstract. Other metabolites showed significant associations with improvements in cirrhosis scores and inflammatory status.", "population_specificity": "HIV/HCV-coinfected patients with advanced HCV-related cirrhosis (n=49).", "effective_dosage": "Not specified", "study_duration": "36 weeks after sustained virologic response (SVR)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:16.551771+00:00"}
{"study_id": 102955, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the perioperative outcomes of two surgical approaches (dorsal and ventral) for laparoscopic left hemihepatectomy, focusing on MHV exposure quality and postoperative complications.", "results_summary": "The dorsal approach showed comparable operative time and blood loss to the ventral approach but had better MHV exposure quality and fewer postoperative complications, including lower increases in liver enzymes (AST and ALT).", "population_specificity": "38 patients who underwent laparoscopic left hemihepatectomy across four university hospitals (2016\u20132021).", "effective_dosage": "Not applicable", "study_duration": "Perioperative period (up to 7 days post-surgery).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:16.839366+00:00"}
{"study_id": 102954, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the long-term safety and efficacy of duodenal mucosal resurfacing (DMR) on metabolic parameters, including alanine aminotransferase (ALT) levels, in patients with type 2 diabetes.", "results_summary": "The study found sustained reductions in HbA1c and ALT levels over 24 months post-DMR, along with improvements in HDL and TG/HDL ratios, indicating durable metabolic benefits. No serious adverse events related to the procedure were reported between 12-24 months.", "population_specificity": "Patients with type 2 diabetes (HbA1c 7.5-10.0%) on oral medication.", "effective_dosage": "Not specified (endoscopic procedure, not a supplement).", "study_duration": "24 months of follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:17.547708+00:00"}
{"study_id": 102958, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to identify causal relationships between gut microbiome features and blood metabolites, including alanine.", "results_summary": "The study found that alanine, along with other metabolites like glutamate and selenium, influenced members of Proteobacteria in the gut microbiome. No direct health outcomes related to alanine were reported.", "population_specificity": "3,432 Chinese individuals with whole-genome, whole-metagenome, anthropometric, and blood metabolic trait data.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:17.723919+00:00"}
{"study_id": 102952, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to assess the efficacy and safety of recaticimab (a PCSK9 inhibitor) as an add-on therapy for patients with hypercholesterolemia, focusing on LDL-C reduction and adverse effects.", "results_summary": "Recaticimab significantly reduced LDL-C levels by 48.37% to 59.51% compared to placebo, with no serious treatment-emergent adverse events reported; common mild adverse events included increased alanine aminotransferase and upper respiratory tract infections.", "population_specificity": "Patients with hypercholesterolemia receiving stable doses of atorvastatin (10 or 20 mg/day) and baseline LDL-C levels \u22652.6 mmol/L.", "effective_dosage": "75 mg every 4 weeks (75Q4W), 150 mg every 8 weeks (150Q8W), 300 mg every 12 weeks (300Q12W), 150 mg every 4 weeks (150Q4W), 300 mg every 8 weeks (300Q8W), and 450 mg every 12 weeks (450Q12W).", "study_duration": "16 weeks for Q4W and Q8W schedules, 24 weeks for Q12W schedule.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:18.654825+00:00"}
{"study_id": 102957, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the clinical, histological, and molecular features of never-decompensated alcohol-related liver disease (ndALD) and alcohol-related hepatitis (AH), focusing on liver function and gene expression.", "results_summary": "The study found that AH patients had worse liver function, higher mortality, and distinct histological and gene expression profiles compared to ndALD patients, with marked deregulation of genes involved in hepatocyte reprogramming and bile acid metabolism in AH.", "population_specificity": "Patients with never-decompensated alcohol-related liver disease (ndALD, n=110) and alcohol-related hepatitis (AH, n=225).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:19.132951+00:00"}
{"study_id": 102956, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to assess the combination of camrelizumab and apatinib as a second-line treatment for advanced oesophageal squamous cell carcinoma, not specifically focused on Alanine.", "results_summary": "The study found that camrelizumab combined with apatinib showed promising activity and manageable toxicity, with 34.6% of patients achieving a confirmed objective response. Increased alanine aminotransferase was reported as a grade 3 or worse treatment-related adverse event in 10% of patients.", "population_specificity": "Patients aged 18-75 years with unresectable locally advanced, locally recurrent, or metastatic oesophageal squamous cell carcinoma who had progressed after or were intolerant to first-line chemotherapy.", "effective_dosage": "Not applicable (study did not focus on Alanine supplementation).", "study_duration": "Until disease progression, unacceptable adverse events, or withdrawal of consent (median follow-up 7.5 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:19.733435+00:00"}
{"study_id": 102960, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The abstract does not provide specific results regarding Alanine, as the focus is on GLP-1RAs. The study conducted a systematic review and meta-analysis of randomized controlled trials to assess these outcomes.", "population_specificity": "Patients with T2DM and NAFLD.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:22.609382+00:00"}
{"study_id": 102961, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not investigate Alanine; it focused on the safety and efficacy of stereotactic ablative body radiotherapy (SABR) and pembrolizumab in oligometastatic clear cell renal cell carcinoma (ccRCC).", "results_summary": "The study did not report any findings related to Alanine.", "population_specificity": "Patients with oligometastatic clear cell renal cell carcinoma (ccRCC).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:25.286377+00:00"}
{"study_id": 102963, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the epidemiological and clinical features of NAFLD and MAFLD, including the role of alanine aminotransferase (ALT) in identifying liver damage.", "results_summary": "The study found that the MAFLD-only group had significantly higher alanine aminotransferase (ALT) levels (mean difference: 8.0 U/L) compared to the NAFLD-only group, indicating greater liver damage in the MAFLD-defined population.", "population_specificity": "General and non-general populations with fatty liver disease (9,808,677 individuals).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:27.342372+00:00"}
{"study_id": 102964, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the current literature on NAFLD and NASH, including the role of alanine aminotransferase as a diagnostic marker in children and adults.", "results_summary": "The study found that alanine aminotransferase levels are used as a diagnostic marker for NAFLD in children, while adults have access to additional noninvasive tests. NAFLD and NASH prevalence varies significantly between children and adults, with NASH posing a higher risk of progressive liver disease.", "population_specificity": "Children and adults with NAFLD or NASH.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:27.434779+00:00"}
{"study_id": 102965, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to compare the efficacy and safety of calcineurin inhibitor (CNI) combined with Tripterygium wilfordii polyglycoside tablets (TWPs) versus CNI combined with glucocorticoids (GCs) in treating idiopathic membranous nephropathy (IMN).", "results_summary": "Both treatment groups showed significant reductions in 24-hour urine protein levels, with the TWP group showing faster reduction at the 6-month mark. No significant differences were observed in overall changes for most biomarkers, and side effects were minimal and comparable between groups.", "population_specificity": "Patients with idiopathic membranous nephropathy (IMN) treated at the Affiliated Hospital of Shandong University of Traditional Chinese Medicine.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:29.943673+00:00"}
{"study_id": 102967, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the hepatitis B surface antigen (HBsAg) reduction potential of switching from entecavir (ETV) to tenofovir disoproxil fumarate (TDF) in HBeAg-positive chronic hepatitis B patients with undetectable serum HBV-DNA.", "results_summary": "At week 48, only 4% of participants achieved a 0.25 log reduction in HBsAg, indicating limited HBsAg reduction after switching from ETV to TDF. The study concluded that further investigation is needed to understand the clinical impact of this switch.", "population_specificity": "HBeAg-positive chronic hepatitis B patients with undetectable serum HBV-DNA.", "effective_dosage": "TDF 300 mg once daily.", "study_duration": "96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:30.621339+00:00"}
{"study_id": 102966, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to assess the hepatic safety of cipargamin (KAE609) across a wide range of doses in patients with uncomplicated falciparum malaria, comparing it to artemether-lumefantrine.", "results_summary": "The study found no significant difference in hepatic adverse events between cipargamin and artemether-lumefantrine, with cipargamin being well-tolerated and showing no safety concerns. Cipargamin exposure was comparable to or higher than in previous studies, and hepatic safety profiles were similar across all doses.", "population_specificity": "Adults with uncomplicated falciparum malaria in five sub-Saharan African countries.", "effective_dosage": "Single doses of 10 to 150 mg and 10 to 50 mg once daily for 3 days.", "study_duration": "3 days (for the 10 to 50 mg once daily regimen).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:31.219755+00:00"}
{"study_id": 102969, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effectiveness of TACE combined with a targeted nanoparticle delivery system for sorafenib in treating hepatocellular carcinoma (HCC) with microvascular invasion.", "results_summary": "The study found no significant differences in liver function and blood test results between the experimental group (TACE + Ab-SFB-NP) and the control group (TACE + non-nano drug delivery system) one month after treatment.", "population_specificity": "42 HCC patients with microvascular invasion after liver cancer surgery.", "effective_dosage": "Not specified", "study_duration": "One month post-treatment follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:31.823026+00:00"}
{"study_id": 102962, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were attempting to determine the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to androgen-deprivation therapy (ADT) in men with high-risk non-metastatic prostate cancer.", "results_summary": "The study found that combination therapy significantly improved metastasis-free survival compared to ADT alone, with a hazard ratio of 0.53 (95% CI 0.44-0.64, p<0.0001). No significant difference was observed between the addition of enzalutamide and abiraterone acetate alone.", "population_specificity": "Men with high-risk non-metastatic prostate cancer (node positive or node negative with high-risk features).", "effective_dosage": "Abiraterone acetate (1000 mg daily), prednisolone (5 mg daily), and enzalutamide (160 mg daily, in the second trial).", "study_duration": "ADT was given for 3 years, and combination therapy for 2 years (unless radiotherapy was omitted, in which case treatment continued until progression).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:32.268289+00:00"}
{"study_id": 102970, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the efficacy of camrelizumab plus transarterial chemoembolization (TACE) compared to TACE alone in patients with massive hepatocellular carcinoma (HCC).", "results_summary": "The study found that camrelizumab plus TACE significantly improved liver function and treatment efficacy compared to TACE alone, with fewer required TACE sessions in the study group.", "population_specificity": "Patients with massive hepatocellular carcinoma (HCC) (n=92).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Follow-up ranged from 7 to 24 months (median 12 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:36.896387+00:00"}
{"study_id": 102972, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of a tailored probiotic and micronutrient mixture on serum alanine aminotransferase (ALAT) levels in obese patients after mini gastric bypass surgery.", "results_summary": "The study found no significant difference in serum ALAT changes between groups, but the tailored probiotic and micronutrient mixture improved other NAFLD-related markers, including serum ASAT, NAFLD fibrosis score, triglycerides, and visceral adiposity index.", "population_specificity": "Obese patients (age: 40 \u00b1 10 y; BMI: 44 \u00b1 3 kg/m\u00b2) who underwent mini gastric bypass surgery.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:37.517820+00:00"}
{"study_id": 102975, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to identify biomarkers of appetite response using a dose-rising whey protein preload intervention, which may include Alanine as a component.", "results_summary": "The abstract does not provide specific findings regarding Alanine's effects.", "population_specificity": "Female participants (n=24) with BMI between 23 and 40 kg/m\u00b2.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:38.485465+00:00"}
{"study_id": 102971, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify high-risk factors and develop a predictive model (BNR-6) for biochemical nonresolution (BNR) in patients with chronic drug-induced liver injury (DILI), focusing on alanine aminotransferase and other liver function markers.", "results_summary": "The study found that significant liver inflammation and fibrosis stages were strongly associated with BNR, with a 21.3-fold increased risk in patients with significant inflammation. The BNR-6 model, incorporating biochemical and demographic factors, effectively predicted BNR with a concordance index of 0.824.", "population_specificity": "Patients with chronic DILI (n=3655, with 2866 undergoing liver biopsy) from nine hospitals.", "effective_dosage": "Not specified", "study_duration": "Follow-up period of over 1 year.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:38.890008+00:00"}
{"study_id": 102974, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers compared the antitumor efficacy and adverse effects of crizotinib and alectinib in ALK-positive non-small cell lung cancer (NSCLC) patients.", "results_summary": "Alectinib showed superior efficacy in progression-free survival, overall survival, CNS progression-free survival, and objective response rate compared to crizotinib, with fewer severe adverse effects. The crizotinib group reported higher rates of gastrointestinal and hepatic adverse effects, including elevated alanine aminotransferase levels.", "population_specificity": "ALK-positive non-small cell lung cancer (NSCLC) patients.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:40.539954+00:00"}
{"study_id": 102978, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize recent advances in novel clinical biomarkers for drug-induced liver injury (DILI) and evaluate their potential to complement traditional biomarkers like alanine aminotransferase (ALT).", "results_summary": "The abstract highlights that traditional biomarkers like ALT lack specificity and sensitivity for DILI prediction, diagnosis, and prognosis, and discusses the potential of novel biomarkers to address these limitations. However, it notes that most reported biomarkers still lack comprehensive information and more specific DILI biomarkers are needed.", "population_specificity": "Not specified (general discussion of clinical biomarkers for DILI)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:42.115077+00:00"}
{"study_id": 102976, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers examined the effects of dietary sugar restriction on hepatic de novo lipogenesis (DNL) and its correlation with metabolic outcomes, including alanine aminotransferase (ALT), in adolescents with NAFLD.", "results_summary": "The study found that dietary sugar restriction significantly reduced hepatic DNL and fasting insulin, with a notable correlation between changes in DNL and ALT levels (r = 0.39, P = 0.049), suggesting a metabolic link. However, no direct causal relationship between alanine and outcomes was established.", "population_specificity": "Adolescent boys with nonalcoholic fatty liver disease (NAFLD) (n = 29).", "effective_dosage": "Not specified (dietary intervention focused on sugar restriction).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:42.617422+00:00"}
{"study_id": 102977, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the optimal dose of ponatinib combined with FLAG-IDA for treating blast-phase chronic myeloid leukaemia, not specifically Alanine.", "results_summary": "The study found that ponatinib-FLAG-IDA induced a second chronic phase in 69% of patients, with dose-limiting toxicities including grade 4 increased alanine aminotransferase. Alanine itself was not the focus of the study.", "population_specificity": "Adults (\u226516 years) with Philadelphia chromosome-positive or BCR-ABL1-positive blast-phase chronic myeloid leukaemia.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Up to two cycles of treatment (28 days per cycle).", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:42.993989+00:00"}
{"study_id": 102979, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of tenofovir alafenamide (TAF) in pregnant women with active chronic hepatitis B (CHB) and their infants.", "results_summary": "The study found that TAF administered throughout or beginning in early pregnancy was generally safe and effective for pregnant women with active CHB and their infants, with no significant adverse events reported.", "population_specificity": "Pregnant women with active chronic hepatitis B (immune clearance and reactivation phases) and their infants.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:46.159374+00:00"}
{"study_id": 102980, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 65, "study_goal": "The researchers aimed to investigate the effects of valproate (VPA) treatment on gut microbiota and its association with metabolic parameters, including alanine aminotransferase, in patients with epilepsy.", "results_summary": "VPA treatment did not significantly alter gut microbiota richness or complexity but increased the Firmicutes to Bacteriodetes ratio. Specific fecal taxa correlated with VPA-related metabolic parameters, including alanine aminotransferase, suggesting a potential role in VPA-induced metabolic disorders.", "population_specificity": "10 newly diagnosed, treatment-na\u00efve patients with cryptogenic epilepsy.", "effective_dosage": "1000 mg daily doses of VPA.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:47.046300+00:00"}
{"study_id": 102982, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of probiotics, including their impact on alanine aminotransferase (ALT) levels, in improving liver function and reducing blood lipid levels in patients with NAFLD.", "results_summary": "Probiotic therapy significantly reduced serum ALT, AST, and total cholesterol levels in NAFLD patients, though it did not affect BMI, HOMA-IR, or TNF. Subgroup analyses suggested that specific probiotic combinations or longer treatment durations could reduce BMI.", "population_specificity": "352 patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Varied, with some treatments lasting more than three months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:48.794421+00:00"}
{"study_id": 102983, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether microecological agents, including potential effects related to alanine metabolism, could improve immune function and alleviate endotoxemia and hyperbilirubinemia in patients with hepatocellular carcinoma after hepatectomy.", "results_summary": "Microecological agents significantly reduced total bilirubin levels and postoperative infection risk but did not show significant effects on ALT, AST, prothrombin, or CRP levels. The study confirmed their benefits for immune function and certain metabolic outcomes.", "population_specificity": "Patients with hepatocellular carcinoma undergoing hepatectomy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:50.065244+00:00"}
{"study_id": 102981, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify risk factors, including raised alanine transaminase levels, associated with hepatocellular carcinoma (HCC) in patients with type 2 diabetes mellitus (T2DM).", "results_summary": "The study found that raised alanine transaminase levels were a significant risk factor for HCC in T2DM patients (AOR = 2.11, 95% CI: 1.16-3.86), indicating a moderate association. No direct efficacy of alanine itself was studied, but its elevated levels correlated with increased HCC risk.", "population_specificity": "T2DM patients from two hepatobiliary referral centers in a developing country (212 case-control pairs).", "effective_dosage": "Not available", "study_duration": "Data extracted from medical records between 1 January 2012 and 30 June 2018 (retrospective analysis).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:50.608770+00:00"}
{"study_id": 102984, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and toxicity of combined neonatal prophylaxis (CNP) in infants at high-risk of HIV-1 perinatal transmission, comparing it to monotherapy with zidovudine.", "results_summary": "The study found no significant differences in increased alanine aminotransferase levels between infants receiving CNP and those on monotherapy, suggesting no adverse effects related to alanine. However, CNP was associated with higher rates of anemia and neutropenia, though severe cases were not significantly different between groups.", "population_specificity": "Newborns at high-risk of HIV-1 perinatal transmission in the Madrid Cohort (2000-2019).", "effective_dosage": "Not specified for alanine.", "study_duration": "Varies (long course: 6 weeks; short course: 4 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:53.307787+00:00"}
{"study_id": 102985, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the effectiveness of entecavir co-administered with DAA in preventing HBV virologic and clinical reactivation in HCV/HBV dually infected patients.", "results_summary": "The study found that co-administration of entecavir with DAA significantly reduced HBV reactivation during treatment (0% in groups 2 and 3 vs. 50% in group 1), though reactivation occurred post-treatment in most cases. Clinical reactivation was rare (5.4%) and not linked to entecavir use.", "population_specificity": "Noncirrhotic patients with dual HCV/HBV infection.", "effective_dosage": "12 weeks of entecavir (group 2) or 24 weeks of entecavir (group 3) alongside 12 weeks of DAA.", "study_duration": "72 weeks total (12 weeks DAA \u00b1 12 or 24 weeks entecavir).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:55.302551+00:00"}
